N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine d3 receptor

ABSTRACT

The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R a  which is/are selected, independently of each other, from halogen, CN, NO 2 , CO 2 R 4 , COR 5 , C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R b , which is/are selected from halogen, NO 2 , CN, CO 2 R 4 , COR 5 , C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl, with it also being possible for two radicals R b  which are bonded to adjacent C atoms of Ar to be together C 3 -C 4 -alkylene; R 1  is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl, C 1 -C 4 -hydroxyalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 3 -C 4 -alkenyl or C 3 -C 4 -alkynyl; with the radicals n, R 1 , R 2 , R 3 , R 4  and R 5  having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims  1  to  10  and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D 3  receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.

The present invention relates to novelN-[(piperazinyl)hetaryl]arylsulfonamide compounds. The compounds possessvaluable therapeutic properties and are suitable, in particular, fortreating diseases which respond to modulation of the dopamine D₃receptor.

Neurons obtain their information by way of G protein-coupled receptors,inter alia. A large number of substances exert their effect by way ofthese receptors. One of them is dopamine. Confirmed findings exist withregard to the presence of dopamine and its physiological function as aneurotransmitter. Disturbances in the dopaminergic transmitter systemresult in diseases of the central nervous system which include, forexample, schizophrenia, depression and Parkinson's disease. Thesediseases, and others, are treated with drugs which interact with thedopamine receptors.

Up until 1990, two subtypes of dopamine receptor had been clearlydefined pharmacologically, namely the D₁ and D₂ receptors. Morerecently, a third subtype was found, namely the D₃ receptor whichappears to mediate some effects of antipsychotics and antiparkinsonians(J. C. Schwartz et al., The Dopamine D₃ Receptor as a Target forAntipsychotics, in Novel Antipsychotic Drugs, H. Y. Meltzer, Ed. RavenPress, New York 1992, pages 135-144; M. Dooley et al., Drugs and Aging1998, 12, 495-514, J. N. Joyce, Pharmacology and Therapeutics 2001, 90,pp. 231-59 “The Dopamine D₃ Receptor as a Therapeutic Target forAntipsychotic and Antiparkinsonian Drugs”).

Since then, the dopamine receptors have been divided into two families.On the one hand, there is the D₂ group, consisting of D₂, D₃ and D₄receptors, and, on the other hand, the D₁ group, consisting of D₁ and D₅receptors. Whereas D₁ and D₂ receptors are widely distributed, D₃receptors appear to be expressed regioselectively. Thus, these receptorsare preferentially to be found in the limbic system and the projectionregions of the mesolimbic dopamine system, especially in the nucleusaccumbens, but also in other regions, such as the amygdala. Because ofthis comparatively regioselective expression, D₃ receptors are regardedas being a target having few side-effects and it is assumed that while aselective D₃ ligand would have the properties of known antipsychotics,it would not have their dopamine D₂ receptor-mediated neurologicalside-effects (P. Sokoloff et al., Localization and Function of the D₃Dopamine Receptor, Arzneim. Forsch./Drug Res. 42(1), 224 (1992); P.Sokoloff et al. Molecular Cloning and Characterization of a NovelDopamine Receptor (D₃) as a Target for Neuroleptics, Nature, 347, 146(1990)).

Compounds having an affinity for the dopamine D₃ receptor have beendescribed in the prior art on various occasions, e.g. in WO 96/02519, WO96/02520, WO 96/02249, WO 96/02246 and DE 10131543 and WO 99/02503. Someof these compounds possess high affinities for the dopamine D₃ receptor.They have therefore been proposed as being suitable for treatingdiseases of the central nervous system. Some of the compounds describedin these publications possess a piperazinylhetaryl structure.

The invention is based on the object of providing compounds which act asselective dopamine D₃ receptor ligands.

This object is achieved by means ofN-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formulaI

in which

-   R is oxygen, a group N—R³ or a group CR^(3a)R^(3b);-   Q is a bivalent, 6-membered heteroaromatic radical which possesses 1    or 2 N atoms as ring members and which optionally carries one or two    substituents R^(a) which is/are selected, independently of each    other, from halogen, CN, NO₂, CO₂R⁴, COR⁵, C₁-C₄-alkyl,    C₁-C₄-alkoxy, C₁-C₄-haloalkyl, NH₂, NHR⁶, NR⁶R⁷ and    C₁-C₄-haloalkoxy;-   Ar is phenyl or a 6-membered heteroaromatic radical which possesses    1 or 2 N atoms as ring members and which optionally carries one or    two substituents R^(b), which is/are selected from halogen, NO₂, CN,    CO₂R⁴, COR⁵, NH₂, NHR⁶, NR⁶R⁷, C₁-C₆-alkyl, C₁-C₆-haloalkyl,    C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl,    C₃-C₆-cycloalkyl, C₃-C₆-cycloalkoxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyl    and C₁-C₄-haloalkyl, with it also being possible for two radicals    R^(1b) which are bonded to adjacent C atoms of Ar to be together    C₃-C₄-alkylene;-   n is 0, 1 or 2;-   R¹ is hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl,    C₃-C₆-cycloalkyl-C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl,    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkynyl;-   R² is C₁-C₄-alkyl, C₁-C₄-haloalkyl or, together with R¹, is    C₂-C₅-alkylene or, in the case of n=2, the two radicals R² can    together be C₁-C₄-alkylene;-   R³ is hydrogen or C₁-C₄-alkyl;-   R^(3a), R^(3b) are, independently of each other, hydrogen or    C₁-C₄-alkyl;-   R⁴ is C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl C₃-C₆-cycloalkyl,    C₃-C₆-cycloalkyl-C₁-C₄-alkyl, phenyl or benzyl;-   R⁵ is hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl    C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl-C₁-C₄alkyl, phenyl or benzyl; and-   R⁶, R⁷ are each independently selected from C₁-C₄-alkyl,    C₁-C₄-haloalkyl or together with the nitrogen to which they are    bound form a saturated 3-, 4-, 5- or 6-membered heterocycle, which    additionally may comprise an oxygen atom or an additional nitrogen    atom as a ring member and which may carry 1, 2, 3 or 4 C₁-C₄ alkyl    groups;    the N-oxides thereof and the physiologically tolerated acid addition    salts of these compounds.

These compounds have not previously been described, with the exceptionof 4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamideand4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide,which are offered for sale by Ambinter, Paris, as test substances forexploratory libraries.

The present invention therefore relates toN-piperazinyl)hetaryl]arylsulfonamide compounds of the general formulaI, to their N-oxides and to their physiologically tolerated acidaddition salts, with the exception of the compounds4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamideand4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.

The present invention also relates to the use ofN-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formulaI, of their N-oxides and of their acid addition salts for producing apharmaceutical composition for treating diseases which respond to theinfluence of dopamine-D₃ receptor antagonists or agonists.

The diseases which respond to the influence of dopamine D₃ receptorantagonists or agonists include, in particular, disturbances anddiseases of the central nervous system, in particular affectivedisturbances, neurotic disturbances, stress disturbances and somatoformdisturbances and psychoses, especially schizophrenia and depression and,in addition, disturbances of kidney function, in particular kidneyfunction disturbances which are caused by diabetes mellitus (see WO00/67847).

According to the invention, at least one compound of the general formulaI having the meanings mentioned at the outset is used for treating theabovementioned indications. Provided the compounds of the formula Ipossess one or more centers of asymmetry, it is also possible to useenantiomeric mixtures, in particular racemates, diastereomeric mixturesand tautomeric mixtures, preferably, however, the respective essentiallypure enantiomers, diastereomers and tautomers.

It is likewise possible to use physiologically tolerated salts of thecompounds of the formula I, especially acid addition salts withphysiologically tolerated acids. Examples of suitable physiologicallytolerated organic and inorganic acids are hydrochloric acid, hydrobromicacid, phosphoric acid, sulfuric acid, C₁-C₄alkylsulfonic acids, such asmethanesulfonic acid, aromatic sulfonic acids, such as benzenesulfonicacid and toluenesulfonic acid, oxalic acid, maleic acid, fumaric acid,lactic acid, tartaric acid, adipic acid and benzoic acid. Otherutilizable acids are described in Fortschritte der Arzneimittelforschung[Advances in drug research], Volume 10, pages 224 ff., Birkhä userVerlag, Basel and Stuttgart, 1966.

It is likewise possible to use N-oxides of the compounds of the formulaI. In the N-oxides of the compounds of the formula I, one or more of theN atoms which is/are ring members, and in particular ring members in thearomatic heterocycles Q and/or Ar, are present as an N-oxide group.Preference is given to those N-oxides of the formula I in which the ringnitrogen atoms in the piperazine ring do not form any N-oxide group.Particularly preferred N-oxides exhibit a N-oxide group on one or two ofthe ring nitrogen atoms of Ar and/or Q.

Here and in that which follows, halogen is fluorine, chlorine, bromineor iodine.

C_(n)-C_(m)-Alkyl (in radicals such as alkoxy, alkoxyalkyl, alkylthio,alkylamino, dialkylamino etc., as well) is a straight-chain or branchedalkyl group having from n to m carbon atoms, e.g. from 1 to 4 carbonatoms. Examples of an alkyl group are methyl, ethyl, n-propyl,iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 2-pentyl,neopentyl, n-hexyl and the like.

C₁-C₄-Haloalkyl (in radicals such as haloalkoxy, haloalkoxyalkyl,haloalkylthio, etc., as well) is an alkyl group having from 1 to 4 Catoms in which all or some, e.g. 1, 2, 3 or 4 of the hydrogen atoms,is/are replaced by halogen atoms, in particular by chlorine or fluorine.Preferred haloalkyl is C₁-C₂-fluoroalkyl or C₁-C₂-fluorochloroalkyl, inparticular CF₃, CHF₂, CF₂Cl, CH₂F, and CH₂CF₃.

C₁-C₄-Hydroxyalkyl is a C₁-C₄-alkyl group which possesses an OH group,such as 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl,2-hydroxybutyl, 3-hydroxybutyl, 2-methyl-2-hydroxypropyl etc.

C₁-C₄-Alkoxy-C₁-C₄-alkyl is a C₁-C₄-alkyl group which carries aC₁-C₄-alkoxy substituent, e.g. methoxymethyl, ethoxymethyl,2-methoxyethyl, 1-methoxyethyl, 2-ethoxyethyl, 1-ethoxyethyl,n-propoxymethyl, isopropoxymethyl, n-butoxymethyl,(1-methylpropoxy)methyl, (2-methylpropoxy)methyl, CH₂—OC(CH₃)₃,2-(methoxy)ethyl, 2-(ethoxy)ethyl, 2-(n-propoxy)ethyl,2-(1-methylethoxy)ethyl, 2-(n-butoxy)ethyl, 2-(1-methylpropoxy)ethyl,2-(2-methylpropoxy)ethyl, 2-(1′,1-dimethylethoxy)ethyl,2-(methoxy)propyl, 2-(ethoxy)propyl, 2-(n-propoxy)propyl,2-(1-methylethoxy)propyl, 2-(n-butoxy)propyl, 2-(1-methylpropoxy)propyl,2-(2-methylpropoxy)propyl, 2-(1,1-dimethylethoxy)propyl,3-(methoxy)propyl, 3-(ethoxy)propyl, 3-(n-propoxy)propyl,3-(1-methylethoxy)propyl, 3-(n-butoxy)propyl, 3-(1-methylpropoxy)propyl,3-(2-methyl-propoxy)propyl, 3-(1,1-dimethylethoxy)propyl,2-(methoxy)butyl, 2-(ethoxy)butyl, 2-(n-propoxy)butyl,2-(1-methylethoxy)butyl, 2-(n-butoxy)butyl, 2-(1-methylpropoxy)butyl,2-(2-methylpropoxy)butyl, 2-(1,1-dimethylethoxy)butyl, 3-(methoxy)butyl,3-(ethoxy)butyl, 3-(n-propoxy)butyl, 3-(1-methylethoxy)butyl,3-(n-butoxy)butyl, 3-(1-methylpropoxy)butyl, 3-(2-methylpropoxy)butyl,3-(1,1-dimethylethoxy)butyl, 4-(methoxy)butyl, 4-(ethoxy)butyl,4-(n-propoxy)butyl, 4-(1-methylethoxy)butyl, 4-(n-butoxy)butyl,4-(1-methylpropoxy)butyl, 4-(2-methylpropoxy)butyl or4-(1,1-dimethylethoxy)butyl, preferably methoxymethyl, ethoxymethyl,2-methoxyethyl, 2-ethoxyethyl, 2-(methoxy)propyl, 2-(ethoxy)propyl or3-(methoxy)propyl, or 3-(ethoxy)propyl.

C₃-C₆-Cycloalkyl is a cycloaliphatic radical having from 3 to 6 C atoms,such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

C₃-C₆-Cycloalkyl-C₁-C₄-alkyl is a C₁-C₄-alkyl group which carries aC₃-C₆-cycloalkyl radical, e.g. cyclopropylmethyl, cyclobutylmethyl,cyclopentylmethyl, 1-cyclopropylethyl, 1-cyclobutylethyl,1-cyclopentylethyl, 2-cyclopropylethyl, 2-cyclobutylethyl,2-cyclopentylethyl, 1-cyclopropylpropyl, 1-cyclobutylpropyl,1-cyclopentylpropyl, 2-cyclopropylpropyl, 2-cyclobutylpropyl,2-cyclopentylpropyl, 3-cyclopropylpropyl, 3-cyclobutylpropyl,3-cyclopentylpropyl, 1-cyclopropyl-1-methylethyl,1-cyclopentyl-1-methylethyl, 1-cyclopentyl-1-methylethyl,3-cyclohexylpropyl, 1-cyclohexyl-1-methylethyl,1-cyclohexyl-1-methylethyl or 1-cyclohexyl-1-methylethyl. C₂-C₄-Alkenyl(in radicals such as alkenyloxy as well) is a singly unsaturatedhydrocarbon radical having 2, 3, 4, 5 or 6 C-atoms, e.g. vinyl,allyl(2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl,methallyl(2-methylprop-2-en-1-yl) and the like. C₃-C₄-Alkenyl is, inparticular, allyl, 1-methylprop-2-en-1-yl, 2-buten-1-yl, 3-buten-1-yl,methallyl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl,1-methylbut-2-en-1-yl or 2-ethylprop-2-en-1-yl.

C₃-C₆-Alkynyl (in radicals such as alkinyloxy as well) is a hydrocarbonradical having 2, 3, 4, 5 or 6 C atoms which possesses a triple bond,e.g. propargyl (2-propyn-1-yl), 1-methylprop-2-yn-1-yl, 2-butyn-1-yl,3-butyn-1-yl, 2-pentyn-1-yl, 1-pentyn-3-yl, etc.

Examples of 6-membered heteroaromatic radicals which possess 1 or 2nitrogen atoms as ring members are, in particular, 2-, 3- or4-pyridinyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-pyrazinyl and 3- or4-pyridazinyl. Examples of bivalent, 6-membered heteroaromatic radicalswhich possess 1 or 2 nitrogen atoms as ring members are, in particular,pyridin-2,4-diyl, pyridin-2,5-diyl, pyridin-2,6-diyl, pyridin-3,5-diyl,pyrimidin-2,4-diyl, pyrimidin-2,5-diyl, pyrimidin-4,6-diyl,pyrazin-2,5-diyl, pyrazin-2,6-diyl, pyridazin-3,6-diyl andpyridazin-3,5-diyl.

With regard to using the compounds according to the invention asdopamine D₃ receptor ligands, preference is given to those compounds offormula I in which the piperazin ring is bonded to the heteroaromaticradical Q in the meta position or, in particular, in the para positionwith respect to the group R.

In one embodiment the radical R^(a) is selected from halogen, CN, NO₂,CO₂R⁴, COR⁵, C₁-C₄-alkyl and C₁-C₄-haloalkyl. Preferred meanings of R⁴and R⁵ are, independently of each other, H or C₁-C₄-alkyl. In anotherembodiment R^(a) is selected from C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, NH₂,NHR⁶ and NR⁶R⁷. In this embodiment preferred meanings of R⁶ and R⁷ areindependently of each other methyl or ethyl.

The heteroaromatic radical Q may be unsubstituted or possess asubstituent R^(a) which is selected from halogen, C₁-C₄-alkyl andC₁-C₄-haloalkyl, C₁-C₄-alkoxy, NH₂, NHR⁶, NR⁶R⁷ and C₁-C₄-haloalkoxy. Inone embodiment the radical R^(a) is selected from halogen, C₁-C₄-alkyland C₁-C₄-haloalkyl. In another preferred embodiment R^(a) is selectedfrom C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, NH₂, NHR⁶ and NR⁶R⁷ with specificpreference given to methoxy, NH₂, methylamino, dimethylamino,ethylamine, diethylamino and methylethylamino.

In a very preferred embodiment, Q is unsubstituted.

In another very preferred embodiment, Q carries a radical selected fromC₁-C₄-haloalkoxy, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-alkyl, NH₂, NHR⁶or NR⁶R⁷. and especially methoxy or methyl.

Preference is given to the variables Q, R¹, R², R³ and Ar preferablyhaving, independently of each other, the meanings given below:

Q is preferably a radical of the formula A:

in which A₁, A₂ and A₃ are, independently of each other, N or CH, andone or two of the variables A₁, A₂ and A₃ can also be C—R^(a), with A₁,A₂ and A₃ not simultaneously being N or being simultaneously selectedfrom CH and C—R^(a). In formula A, k is 0 or 1 and R^(a) has thepreviously mentioned meanings.

In formula A, R^(a) is preferably selected from halogen, especiallychlorine or fluorine, C₁-C₄-alkyl, especially methyl, andC₁-C₄-haloalkyl, especially trifluoromethyl, C₁-C₄-alkoxy especiallymethoxy, C₁-C₄-haloalkoxy, especially difluormethoxy or trifluormethoxy,NH₂, NHR⁶ especially methylamino or ethylamino, and NR⁶R⁷, especiallydimethylamino, diethylamino or methylethylamino. The C atom which islocated between the atoms A₁ and A₃ preferably carries the piperazinylradical.

In particular, none of the variables A₁, A₂ and A₃ is C—R^(a). Preferredradicals Q are those of formula A, in which A₁ and/or A₃ is/are N, theremaining variable A₁ or A₂ is CH or C—R^(a), A₂ is CH, and thepiperazinyl radical is bonded to the C atom which is located between A₁and A₃.

Preference is furthermore given to compounds of the formula I, in whichA₁ and A₂ in formula A are N and A₃ is CH or C—R^(a).

In a very preferred embodiment k in formula A is 0. In particular, Q ispyridin-2,5-diyl or pyrimidin-2,5-diyl which are unsubstituted or ableto possess a substituent R^(a) which is different from hydrogen. Thepiperazinyl radical is then preferably arranged in the 2 position.

In another very preferred embodiment k in formula A is 1, A₃ is N, A₁and A₂ are, independently of each other, N or CH and R^(a) is selectedfrom C₁-C₄-alkoxy, NH₂, NHR⁶, NR⁶R⁷ and C₁-C₄haloalkoxy. In particularR^(a) is methoxy or methyl. Most preferably the piperazine radical islocated in the 2 position. In this embodiment compounds are especiallypreferred, in which A₁ is N or CH, in particular CH and A₂ is CH.

Ar is preferably phenyl or pyridyl which, where appropriate, possessesone or two of the abovementioned substituents R^(b). With regard tousing the compounds according to the invention as dopamine D₃ receptorligands, preference is given to those compounds of formula I in which Arcarries one substituent R^(b) in the para position and, whereappropriate, a further substituent R^(b) in the ortho position or in themetaposition, in each case related to the binding site for thesulfonamide group. The radicals R^(b) may be identical or different.Preference is given to the radicals R^(b) in the para position beingselected from C₂-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,C₃-C₆-cycloalkyl, NH₂, NHR⁶ and NR⁶R⁷.

In one preferred embodiment the radical R^(b) in the para position isselected from C₂-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,C₃-C₆-cycloalkyl, in particular, from branched C₃-C₆-alkyl, especiallyisopropyl, and C₃-C₆-cycloalkyl, especially cyclopropyl. Very particularpreference is given to the radical R^(b) which is arranged in the paraposition of Ar being isopropyl.

In one preferred embodiment the radical R^(b) in the para position isselected from NHR⁶ and NR⁶R⁷. In this embodiment preferred meanings ofR⁶ and R⁷ are independently of each other methyl or ethyl or formtogether with the N atom a saturated 3-, 4-, 5- or 6-memberedheterocycle, which additionally may comprise an oxygen atom or anadditional nitrogen atom as a Ting member and which may carry 1, 2, 3 or4 C₁-C₄ alkyl groups, e.g. a radical from the group consisting ofaziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl etc.

Preferred radicals R^(b) in the meta position or ortho position areselected from halogen, especially chlorine and fluorine, C₁-C₄-alkyl,especially methyl, CN, trifluoromethyl and difluoromethyl.

With regard to using the compounds according to the invention asdopamine D₃ receptor ligands, preference is given to those compounds ofthe formula I in which R¹ is different from hydrogen, in particularhydrogen and methyl. In particular, R¹ is C₂-C₃-alkyl, cyclopropylmethylor, particularly preferably, ethyl, allyl or n-propyl.

The variable n is preferably 0 or 1. Provided n is ≠0, R² is preferablymethyl. When n is ≠0, the group R² is preferably bonded to a carbon atomin the piperazine ring which is adjacent to the group R¹—N. Inparticularly preferred compounds, n=0. Particular preference is alsogiven to compounds of the formula I in which it applies that n=1 and R²is a methyl group which is bonded to a carbon atom in the piperazinering which is adjacent to the group R¹—N. The compounds can then bepresent as a racemate, as pure enantiomers or as nonracemic mixtures ofthe enantiomers. Among these, particular preference is given to thosecompounds in which the C atom which carries the methyl group exhibitsthe S configuration.

R³ is preferably hydrogen or C₁-C₄-alkyl and, in particular, hydrogen.

If R is a group CR^(3a)R^(3b), at least one of the radicals R^(3a) orR^(3b) is hydrogen. More preferably both radicals R^(3a) and R^(3b) arehydrogen.

Among the compounds of the general formula I, preference is given to thecompounds I, wherein R is N—R³, wherein R³ is as defined above andespecially H. Amongst these compounds preference is given to thecompounds of the general formula Ia

in which n, R¹, R², R³, R^(a) and R^(b) have the previously mentionedmeanings, in particular the meanings specified as being preferred, andin which A₁, A₂ and A₃ are, independently of each other, N or CH, andone of the variables A₁, A₂ and A₃ can also be C—R^(a), with A₁, A₂ andA₃ not simultaneously being N or simultaneously being selected from CHand C—R^(a), and X and Y are selected from CH, C—R^(b′) and N, in whichR^(b′) is halogen, methyl, CN, difluoromethyl or trifluoromethyl, with Xand Y not simultaneously being N or simultaneously being C—R^(b′), and kis 0 or 1. R^(a) has the previously mentioned meanings. In particular,R^(a) is selected from halogen, especially chlorine or fluorine,C₁-C₄-alkyl, especially methyl, and C₁-C₄-haloalkyl, especiallytrifluoromethyl, C₁-C₄-alkoxy especially methoxy, C₁-C₄-haloalkoxy,especially difluormethoxy or trifluormethoxy, NH₂, NHR⁶ especiallymethylamino or ethylamino, and NR⁶R⁷, especially dimethylamino,diethylamino or methylethylamino.

In particular, none of the variables A¹, A² and A³ is C—R^(a). Preferredcompounds Ia are those in which A₁ and/or A₃ is/are N, the remainingvariable A₁ or A₂ is CH or C—R^(a), A₂ is CH.

In particular preferred embodiment, k=0. Among these, preference isfurthermore given to compound I in which A₁ and A₂ are N and A₃ is CH orC—R^(a). Among these, preference is given to those compounds of theformula Ia in which X or Y is CH or N and, in particular, both are CH.

In another very preferred embodiment k in formula Ia is 1, A₃ is N, A₁and A₂ are, independently of each other, N or CH and R^(a) is selectedfrom C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, NH₂, NHR⁶, NR⁶R⁷ andC₁-C₄-haloalkoxy. In particular R^(a) is methoxy or methyl. In thisembodiment compounds are especially preferred, in which A₁ is N or CH,in particular CH and A₂ is CH.

Among the compounds of general formula Ia, preference is given to thecompounds of general formula Ia.1

in which n, X, Y, R¹, R², R³, R^(a) and R^(b) have the previouslymentioned meanings, in particular the meanings specified as beingpreferred, and q is 0, 1 or 2 and in particular 0 or 1. If q is 1, theradical R^(a) is preferably bound to the carbon atom which is adjacentto the nitrogen atom of the pyridine ring

Among the compounds of general formula Ia, preference is furthermoregiven to the compounds of general formula Ia.2

in which n, X, Y, R¹, R², R³, R^(a) and R^(b) have the previouslymentioned meanings, in particular the meanings specified as beingpreferred, and q and q′ are independently of each other 0 or 1, withq+q′ preferably being 0 or 1.

Examples of compounds of the formula Ia.1 are the compounds of thefollowing general formulae Ia.1a, Ia.1b, Ia.1c, Ia.1d, Ia.1e, Ia.1f,Ia.1g, Ia.1h and Ia.1k:

in which R¹, R^(2a), R^(2b), R^(2c), R³, X, Y and R^(b), have themeanings specified in one line in Table 1.

Examples of compounds of the formula Ia.2 are the compounds of thefollowing general formulae Ia.2a, Ia.2b, Ia.2c, Ia.2d and Ia.2e:

in which R¹, R^(2a), R^(2b), R^(2c), R³, X, Y and R^(b) have themeanings specified in one line in Table 1.

TABLE 1 No. R¹ R^(2a) R^(2b) R^(2c) R³ X Y R^(b)  1. H H H H H CH CHCH(CH₃)₂  2. CH₃ H H H H CH CH CH(CH₃)₂  3. CH₂CH₃ H H H H CH CHCH(CH₃)₂  4. CH₂CH═CH₂ H H H H CH CH CH(CH₃)₂  5. CH₂-c-C₃H₅ H H H H CHCH CH(CH₃)₂  6. CH₂CH₂CH₃ H H H H CH CH CH(CH₃)₂  7. H (s)CH₃ H H H CHCH CH(CH₃)₂  8. CH₃ (s)CH₃ H H H CH CH CH(CH₃)₂  9. CH₂CH₃ (s)CH₃ H H HCH CH CH(CH₃)₂  10. CH₂CH═CH₂ (s)CH₃ H H H CH CH CH(CH₃)₂  11.CH₂-c-C₃H₅ (s)CH₃ H H H CH CH CH(CH₃)₂  12. CH₂CH₂CH₃ (s)CH₃ H H H CH CHCH(CH₃)₂  13. CH₃ rac-CH₃ H H H CH CH CH(CH₃)₂  14. CH₂CH═CH₂ rac-CH₃ HH H CH CH CH(CH₃)₂  15. CH₂-c-C₃H₅ rac-CH₃ H H H CH CH CH(CH₃)₂  16.CH₂CH₂CH₃ rac-CH₃ H H H CH CH CH(CH₃)₂  17. CH₃ (R)CH₃ H H H CH CHCH(CH₃)₂  18. CH₂CH═CH₂ (R)CH₃ H H H CH CH CH(CH₃)₂  19. CH₂-c-C₃H₅(R)CH₃ H H H CH CH CH(CH₃)₂  20. CH₂CH₂CH₃ (R)CH₃ H H H CH CH CH(CH₃)₂ 21. CH₃ H CH₃ H H CH CH CH(CH₃)₂  22. CH₂CH═CH₂ H CH₃ H H CH CHCH(CH₃)₂  23. CH₂-c-C₃H₅ H CH₃ H H CH CH CH(CH₃)₂  24. CH₂CH₂CH₃ H CH₃ HH CH CH CH(CH₃)₂  25. CH₃ CH₃ H CH₃ H CH CH CH(CH₃)₂  26. CH₂CH═CH₂ CH₃H CH₃ H CH CH CH(CH₃)₂  27. CH₂-c-C₃H₅ CH₃ H CH₃ H CH CH CH(CH₃)₂  28.CH₂CH₂CH₃ CH₃ H CH₃ H CH CH CH(CH₃)₂  29. CH₃ CH₃ CH₃ H H CH CH CH(CH₃)₂ 30. CH₂CH═CH₂ CH₃ CH₃ H H CH CH CH(CH₃)₂  31. CH₂-c-C₃H₅ CH₃ CH₃ H H CHCH CH(CH₃)₂  32. CH₂CH₂CH₃ CH₃ CH₃ H H CH CH CH(CH₃)₂  33. (s)(CH₂)₃ H HH CH CH CH(CH₃)₂  34. (s)(CH₂)₄ H H H CH CH CH(CH₃)₂  35. rac(CH₂)₃ H HH CH CH CH(CH₃)₂  36. rac (CH₂)₄ H H H CH CH CH(CH₃)₂  37. (R)(CH₂)₃ H HH CH CH CH(CH₃)₂  38. (R)(CH₂)₄ H H H CH CH CH(CH₃)₂  39. CH₂CH═CH₂ H HH H C—Cl CH CH(CH₃)₂  40. CH₂-c-C₃H₅ H H H H C—Cl CH CH(CH₃)₂  41.CH₂CH₂CH₃ H H H H C—Cl CH CH(CH₃)₂  42. CH₂CH═CH₂ (s)CH₃ H H H C—Cl CHCH(CH₃)₂  43. CH₂-c-C₃H₅ (s)CH₃ H H H C—Cl CH CH(CH₃)₂  44. CH₂CH₃(s)CH₃ H H H C—Cl CH CH(CH₃)₂  45. CH₂CH₂CH₃ (s)CH₃ H H H C—Cl CHCH(CH₃)₂  46. CH₂CH═CH₂ rac-CH₃ H H H C—Cl CH CH(CH₃)₂  47. CH₂-c-C₃H₅rac-CH₃ H H H C—Cl CH CH(CH₃)₂  48. CH₂CH₂CH₃ rac-CH₃ H H H C—Cl CHCH(CH₃)₂  49. CH₂CH₃ rac-CH₃ H H H C—Cl CH CH(CH₃)₂  50. CH₂CH═CH₂(R)CH₃ H H H C—Cl CH CH(CH₃)₂  51. CH₂-c-C₃H₅ (R)CH₃ H H H C—Cl CHCH(CH₃)₂  52. CH₂CH₃ (R)CH₃ H H H C—Cl CH CH(CH₃)₂  53. CH₂CH₂CH₃ (R)CH₃H H H C—Cl CH CH(CH₃)₂  54. CH₂CH═CH₂ H CH₃ H H C—Cl CH CH(CH₃)₂  55.CH₂-c-C₃H₅ H CH₃ H H C—Cl CH CH(CH₃)₂  56. CH₂CH₂CH₃ H CH₃ H H C—Cl CHCH(CH₃)₂  57. CH₂CH═CH₂ CH₃ H CH₃ H C—Cl CH CH(CH₃)₂  58. CH₂-c-C₃H₅ CH₃H CH₃ H C—Cl CH CH(CH₃)₂  59. CH₂CH₂CH₃ CH₃ H CH₃ H C—Cl CH CH(CH₃)₂ 60. CH₂CH═CH₂ CH₃ CH₃ H H C—Cl CH CH(CH₃)₂  61. CH₂-c-C₃H₅ CH₃ CH₃ H HC—Cl CH CH(CH₃)₂  62. CH₂CH₂CH₃ CH₃ CH₃ H H C—Cl CH CH(CH₃)₂  63. (CH₂)₃H H H C—Cl CH CH(CH₃)₂  64. (CH₂)₄ H H H C—Cl CH CH(CH₃)₂  65. CH₂CH═CH₂H H H H CH C—Cl CH(CH₃)₂  66. CH₂-c-C₃H₅ H H H H CH C—Cl CH(CH₃)₂  67.CH₂CH₂CH₃ H H H H CH C—Cl CH(CH₃)₂  68. CH₂CH═CH₂ (s)CH₃ H H H CH C—ClCH(CH₃)₂  69. CH₂-c-C₃H₅ (s)CH₃ H H H CH C—Cl CH(CH₃)₂  70. CH₂CH₂CH₃(s)CH₃ H H H CH C—Cl CH(CH₃)₂  71. CH₂CH₃ (s)CH₃ H H H CH C—Cl CH(CH₃)₂ 72. CH₂CH═CH₂ rac-CH₃ H H H CH C—Cl CH(CH₃)₂  73. CH₂-c-C₃H₅ rac-CH₃ HH H CH C—Cl CH(CH₃)₂  74. CH₂CH₂CH₃ rac-CH₃ H H H CH C—Cl CH(CH₃)₂  75.CH₂CH₃ rac-CH₃ H H H CH C—Cl CH(CH₃)₂  76. CH₂CH═CH₂ (R)CH₃ H H H CHC—Cl CH(CH₃)₂  77. CH₂-c-C₃H₅ (R)CH₃ H H H CH C—Cl CH(CH₃)₂  78. CH₂CH₃(R)CH₃ H H H CH C—Cl CH(CH₃)₂  79. CH₂CH₂CH₃ (R)CH₃ H H H CH C—ClCH(CH₃)₂  80. CH₂CH═CH₂ H CH₃ H H CH C—Cl CH(CH₃)₂  81. CH₂-c-C₃H₅ H CH₃H H CH C—Cl CH(CH₃)₂  82. CH₂CH₂CH₃ H CH₃ H H CH C—Cl CH(CH₃)₂  83.CH₂CH═CH₂ CH₃ H CH₃ H CH C—Cl CH(CH₃)₂  84. CH₂-c-C₃H₅ CH₃ H CH₃ H CHC—Cl CH(CH₃)₂  85. CH₂CH₂CH₃ CH₃ H CH₃ H CH C—Cl CH(CH₃)₂  86. CH₂CH═CH₂CH₃ CH₃ H H CH C—Cl CH(CH₃)₂  87. CH₂-c-C₃H₅ CH₃ CH₃ H H CH C—ClCH(CH₃)₂  88. CH₂CH₂CH₃ CH₃ CH₃ H H CH C—Cl CH(CH₃)₂  89. (CH₂)₃ H H HCH C—Cl CH(CH₃)₂  90. (CH₂)₄ H H H CH C—Cl CH(CH₃)₂  91. CH₂CH═CH₂ H H HH C—CH₃ CH CH(CH₃)₂  92. CH₂-c-C₃H₅ H H H H C—CH₃ CH CH(CH₃)₂  93.CH₂CH₂CH₃ H H H H C—CH₃ CH CH(CH₃)₂  94. CH₂CH═CH₂ (s)CH₃ H H H C—CH₃ CHCH(CH₃)₂  95. CH₂-c-C₃H₅ (s)CH₃ H H H C—CH₃ CH CH(CH₃)₂  96. CH₂CH₂CH₃(s)CH₃ H H H C—CH₃ CH CH(CH₃)₂  97. CH₂CH═CH₂ rac-CH₃ H H H C—CH₃ CHCH(CH₃)₂  98. CH₂-c-C₃H₅ rac-CH₃ H H H C—CH₃ CH CH(CH₃)₂  99. CH₂CH₂CH₃rac-CH₃ H H H C—CH₃ CH CH(CH₃)₂ 100 CH₂CH═CH₂ (R)CH₃ H H H C—CH₃ CHCH(CH₃)₂ 101 CH₂-c-C₃H₅ (R)CH₃ H H H C—CH₃ CH CH(CH₃)₂ 102 CH₂CH₂CH₃(R)CH₃ H H H C—CH₃ CH CH(CH₃)₂ 103 CH₂CH═CH₂ H CH₃ H H C—CH₃ CH CH(CH₃)₂104 CH₂-c-C₃H₅ H CH₃ H H C—CH₃ CH CH(CH₃)₂ 105 CH₂CH₂CH₃ H CH₃ H H C—CH₃CH CH(CH₃)₂ 106 CH₂CH═CH₂ CH₃ H CH₃ H C—CH₃ CH CH(CH₃)₂ 107 CH₂-c-C₃H₅CH₃ H CH₃ H C—CH₃ CH CH(CH₃)₂ 108 CH₂CH₂CH₃ CH₃ H CH₃ H C—CH₃ CHCH(CH₃)₂ 109 CH₂CH═CH₂ CH₃ CH₃ H H C—CH₃ CH CH(CH₃)₂ 110 CH₂-c-C₃H₅ CH₃CH₃ H H C—CH₃ CH CH(CH₃)₂ 111 CH₂CH₂CH₃ CH₃ CH₃ H H C—CH₃ CH CH(CH₃)₂112 (CH₂)₃ H H H C—CH₃ CH CH(CH₃)₂ 113 (CH₂)₄ H H H C—CH₃ CH CH(CH₃)₂114 CH₂CH═CH₂ H H H H CH C—CH₃ CH(CH₃)₂ 115 CH₂-c-C₃H₅ H H H H CH C—CH₃CH(CH₃)₂ 116 CH₂CH₂CH₃ H H H H CH C—CH₃ CH(CH₃)₂ 117 CH₂CH═CH₂ (s)CH₃ HH H CH C—CH₃ CH(CH₃)₂ 118 CH₂-c-C₃H₅ (s)CH₃ H H H CH C—CH₃ CH(CH₃)₂ 119CH₂CH₂CH₃ (s)CH₃ H H H CH C—CH₃ CH(CH₃)₂ 120 CH₂CH═CH₂ rac-CH₃ H H H CHC—CH₃ CH(CH₃)₂ 121 CH₂-c-C₃H₅ rac-CH₃ H H H CH C—CH₃ CH(CH₃)₂ 122CH₂CH₂CH₃ rac-CH₃ H H H CH C—CH₃ CH(CH₃)₂ 123 CH₂CH═CH₂ (R)CH₃ H H H CHC—CH₃ CH(CH₃)₂ 124 CH₂-c-C₃H₅ (R)CH₃ H H H CH C—CH₃ CH(CH₃)₂ 125CH₂CH₂CH₃ (T)CH₃ H H H CH C—CH₃ CH(CH₃)₂ 126 CH₂CH═CH₂ H CH₃ H H CHC—CH₃ CH(CH₃)₂ 127 CH₂-c-C₃H₅ H CH₃ H H CH C—CH₃ CH(CH₃)₂ 128 CH₂CH₂CH₃H CH₃ H H CH C—CH₃ CH(CH₃)₂ 129 CH₂CH═CH₂ CH₃ H CH₃ H CH C—CH₃ CH(CH₃)₂130 CH₂-c-C₃H₅ CH₃ H CH₃ H CH C—CH₃ CH(CH₃)₂ 131 CH₂CH₂CH₃ CH₃ H CH₃ HCH C—CH₃ CH(CH₃)₂ 132 CH₂CH═CH₂ CH₃ CH₃ H H CH C—CH₃ CH(CH₃)₂ 133CH₂-c-C₃H₅ CH₃ CH₃ H H CH C—CH₃ CH(CH₃)₂ 134 CH₂CH₂CH₃ CH₃ CH₃ H H CHC—CH₃ CH(CH₃)₂ 135 (CH₂)₃ H H H CH C—CH₃ CH(CH₃)₂ 136 (CH₂)₄ H H H CHC—CH₃ CH(CH₃)₂ 137 H H H H H CH CH c-C₃H₅ 138 CH₃ H H H H CH CH c-C₃H₅139 CH₂CH₃ H H H H CH CH c-C₃H₅ 140 CH₂CH═CH₂ H H H H CH CH c-C₃H₅ 141CH₂-c-C₃H₅ H H H H CH CH c-C₃H₅ 142 CH₂CH₂CH₃ H H H H CH CH c-C₃H₅ 143 H(s)CH₃ H H H CH CH c-C₃H₅ 144 CH₃ (s)CH₃ H H H CH CH c-C₃H₅ 145 CH₂CH₃(s)CH₃ H H H CH CH c-C₃H₅ 146 CH₂CH═CH₂ (s)CH₃ H H H CH CH c-C₃H₅ 147CH₂-c-C₃H₅ (s)CH₃ H H H CH CH c-C₃H₅ 148 CH₂CH₂CH₃ (s)CH₃ H H H CH CHc-C₃H₅ 149 CH₃ rac-CH₃ H H H CH CH c-C₃H₅ 150 CH₂CH═CH₂ rac-CH₃ H H H CHCH c-C₃H₅ 151 CH₂-c-C₃H₅ rac-CH₃ H H H CH CH c-C₃H₅ 152 CH₂CH₂CH₃rac-CH₃ H H H CH CH c-C₃H₅ 153 CH₂CH₃ (R)CH₃ H H H CH CH c-C₃H₅ 154CH₂CH═CH₂ (R)CH₃ H H H CH CH c-C₃H₅ 155 CH₂-c-C₃H₅ (R)CH₃ H H H CH CHc-C₃H₅ 156 CH₂CH₂CH₃ (R)CH₃ H H H CH CH c-C₃H₅ 157 CH₃ H CH₃ H H CH CHc-C₃H₅ 158 CH₂CH═CH₂ H CH₃ H H CH CH c-C₃H₅ 159 CH₂-c-C₃H₅ H CH₃ H H CHCH c-C₃H₅ 160 CH₂CH₂CH₃ H CH₃ H H CH CH c-C₃H₅ 161 CH₃ CH₃ H CH₃ H CH CHc-C₃H₅ 162 CH₂CH═CH₂ CH₃ H CH₃ H CH CH c-C₃H₅ 163 CH₂-c-C₃H₅ CH₃ H CH₃ HCH CH c-C₃H₅ 164 CH₂CH₂CH₃ CH₃ H CH₃ H CH CH c-C₃H₅ 165 CH₃ CH₃ CH₃ H HCH CH c-C₃H₅ 166 CH₂CH═CH₂ CH₃ CH₃ H H CH CH c-C₃H₅ 167 CH₂-c-C₃H₅ CH₃CH₃ H H CH CH c-C₃H₅ 168 CH₂CH₂CH₃ CH₃ CH₃ H H CH CH c-C₃H₅ 169(s)(CH₂)₃ H H H CH CH c-C₃H₅ 170 (s)(CH₂)₄ H H H CH CH c-C₃H₅ 171rac(CH₂)₃ H H H CH CH c-C₃H₅ 172 rac(CH₂)₄ H H H CH CH c-C₃H₅ 173(R)(CH₂)₃ H H H CH CH c-C₃H₅ 174 (R)(CH₂)₄ H H H CH CH c-C₃H₅ 175CH₂CH═CH₂ H H H H CH C—Cl c-C₃H₅ 176 CH₂-c-C₃H₅ H H H H CH C—Cl c-C₃H₅177 CH₂CH₂CH₃ H H H H CH C—Cl c-C₃H₅ 178 CH₂CH═CH₂ (s)CH₃ H H H CH C—Clc-C₃H₅ 179 CH₂-c-C₃H₅ (s)CH₃ H H H CH C—Cl c-C₃H₅ 180 CH₂CH₃ (s)CH₃ H HH CH C—Cl c-C₃H₅ 181 CH₂CH₂CH₃ (s)CH₃ H H H CH C—Cl c-C₃H₅ 182 CH₂CH═CH₂rac-CH₃ H H H CH C—Cl c-C₃H₅ 183 CH₂-c-C₃H₅ rac-CH₃ H H H CH C—Cl c-C₃H₅184 CH₂CH₃ rac-CH₃ H H H CH C—Cl c-C₃H₅ 185 CH₂CH₂CH₃ rac-CH₃ H H H CHC—Cl c-C₃H₅ 186 CH₂CH═CH₂ (R)CH₃ H H H CH C—Cl c-C₃H₅ 187 CH₂-c-C₃H₅(R)CH₃ H H H CH C—Cl c-C₃H₅ 188 CH₂CH₃ (R)CH₃ H H H CH C—Cl c-C₃H₅ 189CH₂CH₂CH₃ (R)CH₃ H H H CH C—Cl c-C₃H₅ 190 CH₂CH═CH₂ H H H H CH C—CH₃c-C₃H₅ 191 CH₂-c-C₃H₅ H H H H CH C—CH₃ c-C₃H₅ 192 CH₂CH₂CH₃ H H H H CHC—CH₃ c-C₃H₅ 193 CH₂CH═CH₂ (s)CH₃ H H H CH C—CH₃ c-C₃H₅ 194 CH₂-c-C₃H₅(s)CH₃ H H H CH C—CH₃ c-C₃H₅ 195 CH₂CH₃ (s)CH₃ H H H CH C—CH₃ c-C₃H₅ 196CH₂CH₂CH₃ (s)CH₃ H H H CH C—CH₃ c-C₃H₅ 197 CH₂CH═CH₂ rac-CH₃ H H H CHC—CH₃ c-C₃H₅ 198 CH₂-c-C₃H₅ rac-CH₃ H H H CH C—CH₃ c-C₃H₅ 199 CH₂CH₃rac-CH₃ H H H CH C—CH₃ c-C₃H₅ 200 CH₂CH₂CH₃ rac-CH₃ H H H CH C—CH₃c-C₃H₅ 201 CH₂CH═CH₂ (R)CH₃ H H H CH C—CH₃ c-C₃H₅ 202 CH₂-c-C₃H₅ (R)CH₃H H H CH C—CH₃ c-C₃H₅ 203 CH₂CH₃ (R)CH₃ H H H CH C—CH₃ c-C₃H₅ 204CH₂CH₂CH₃ (R)CH₃ H H H CH C—CH₃ c-C₃H₅ 205 CH₂CH═CH₂ H H H H C—Cl CHc-C₃H₅ 206 CH₂-c-C₃H₅ H H H H C—Cl CH c-C₃H₅ 207 CH₂CH₂CH₃ H H H H C—ClCH c-C₃H₅ 208 CH₂CH═CH₂ (s)CH₃ H H H C—Cl CH c-C₃H₅ 209 CH₂-c-C₃H₅(s)CH₃ H H H C—Cl CH c-C₃H₅ 210 CH₂CH₂CH₃ (s)CH₃ H H H C—Cl CH c-C₃H₅211 CH₂CH═CH₂ rac-CH₃ H H H C—Cl CH c-C₃H₅ 212 CH₂-c-C₃H₅ rac-CH₃ H H HC—Cl CH c-C₃H₅ 213 CH₂CH₂CH₃ rac-CH₃ H H H C—Cl CH c-C₃H₅ 214 CH₂CH═CH₂H H H H C—CH₃ CH c-C₃H₅ 215 CH₂-c-C₃H₅ H H H H C—CH₃ CH c-C₃H₅ 216CH₂CH₂CH₃ H H H H C—CH₃ CH c-C₃H₅ 217 CH₂CH═CH₂ (s)CH₃ H H H C—CH₃ CHc-C₃H₅ 218 CH₂-c-C₃H₅ (s)CH₃ H H H C—CH₃ CH c-C₃H₅ 219 CH₂CH₃ (s)CH₃ H HH C—CH₃ CH c-C₃H₅ 220 CH₂CH₂CH₃ (s)CH₃ H H H C—CH₃ CH c-C₃H₅ 221CH₂CH═CH₂ rac-CH₃ H H H C—CH₃ CH c-C₃H₅ 222 CH₂-c-C₃H₅ rac-CH₃ H H HC—CH₃ CH c-C₃H₅ 223 CH₂CH₂CH₃ rac-CH₃ H H H C—CH₃ CH c-C₃H₅ 224CH₂CH═CH₂ (R)CH₃ H H H C—CH₃ CH c-C₃H₅ 225 CH₂-c-C₃H₅ (R)CH₃ H H H C—CH₃CH c-C₃H₅ 226 CH₂CH₂CH₃ (R)CH₃ H H H C—CH₃ CH c-C₃H₅ 227 H H H H H CH CHC₂H₅ 228 CH₃ H H H H CH CH C₂H₅ 229 CH₂CH₃ H H H H CH CH C₂H₅ 230CH₂CH═CH₂ H H H H CH CH C₂H₅ 231 CH₂-c-C₃H₅ H H H H CH CH C₂H₅ 232CH₂CH₂CH₃ H H H H CH CH C₂H₅ 233 H (s)CH₃ H H H CH CH C₂H₅ 234 CH₃(s)CH₃ H H H CH CH C₂H₅ 235 CH₂CH₃ (s)CH₃ H H H CH CH C₂H₅ 236 CH₂CH═CH₂(s)CH₃ H H H CH CH C₂H₅ 237 CH₂-c-C₃H₅ (s)CH₃ H H H CH CH C₂H₅ 238CH₂CH₂CH₃ (s)CH₃ H H H CH CH C₂H₅ 239 CH₃ rac-CH₃ H H H CH CH C₂H₅ 240CH₂CH═CH₂ rac-CH₃ H H H CH CH C₂H₅ 241 CH₂-c-C₃H₅ rac-CH₃ H H H CH CHC₂H₅ 242 CH₂CH₂CH₃ rac-CH₃ H H H CH CH C₂H₅ 243 CH₃ (R)CH₃ H H H CH CHC₂H₅ 244 CH₂CH₃ (R)CH₃ H H H CH CH C₂H₅ 245 CH₂CH═CH₂ (R)CH₃ H H H CH CHC₂H₅ 246 CH₂-c-C₃H₅ (R)CH₃ H H H CH CH C₂H₅ 247 CH₂CH₂CH₃ (R)CH₃ H H HCH CH C₂H₅ 248 CH₃ H CH₃ H H CH CH C₂H₅ 249 CH₂CH═CH₂ H CH₃ H H CH CHC₂H₅ 250 CH₂-c-C₃H₅ H CH₃ H H CH CH C₂H₅ 251 CH₂CH₂CH₃ H CH₃ H H CH CHC₂H₅ 252 CH₃ CH₃ H CH₃ H CH CH C₂H₅ 253 CH₂CH═CH₂ CH₃ H CH₃ H CH CH C₂H₅254 CH₂-c-C₃H₅ CH₃ H CH₃ H CH CH C₂H₅ 255 CH₂CH₂CH₃ CH₃ H CH₃ H CH CHC₂H₅ 256 CH₃ CH₃ CH₃ H H CH CH C₂H₅ 257 CH₂CH═CH₂ CH₃ CH₃ H H CH CH C₂H₅258 CH₂-c-C₃H₅ CH₃ CH₃ H H CH CH C₂H₅ 259 CH₂CH₂CH₃ CH₃ CH₃ H H CH CHC₂H₅ 260 (s)(CH₂)₃ H H H CH CH C₂H₅ 261 (s)(CH₂)₄ H H H CH CH C₂H₅ 262rac(CH₂)₃ H H H CH CH C₂H₅ 263 rac(CH₂)₄ H H H CH CH C₂H₅ 264 (R)(CH₂)₃H H H CH CH C₂H₅ 265 (R)(CH₂)₄ H H H CH CH C₂H₅ 266 H H H H H CH CH CH₃267 CH₃ H H H H CH CH CH₃ 268 CH₂CH₃ H H H H CH CH CH₃ 269 CH₂CH═CH₂ H HH H CH CH CH₃ 270 CH₂-c-C₃H₅ H H H H CH CH CH₃ 271 CH₂CH₂CH₃ H H H H CHCH CH₃ 272 H (s)CH₃ H H H CH CH CH₃ 273 CH₃ (s)CH₃ H H H CH CH CH₃ 274CH₂CH₃ (s)CH₃ H H H CH CH CH₃ 275 CH₂CH═CH₂ (s)CH₃ H H H CH CH CH₃ 276CH₂-c-C₃H₅ (s)CH₃ H H H CH CH CH₃ 277 CH₂CH₂CH₃ (s)CH₃ H H H CH CH CH₃278 CH₂CH═CH₂ rac-CH₃ H H H CH CH CH₃ 279 CH₂CH₂CH₃ rac-CH₃ H H H CH CHCH₃ 280 CH₂CH₃ (R)CH₃ H H H CH CH CH₃ 281 CH₂CH═CH₂ (R)CH₃ H H H CH CHCH₃ 282 CH₂-c-C₃H₅ (R)CH₃ H H H CH CH CH₃ 283 CH₂CH₂CH₃ (R)CH₃ H H H CHCH CH₃ 284 CH₂CH═CH₂ H CH₃ H H CH CH CH₃ 285 CH₂CH₂CH₃ H CH₃ H H CH CHCH₃ 286 CH₂CH═CH₂ CH₃ H CH₃ H CH CH CH₃ 287 CH₂CH₂CH₃ CH₃ H CH₃ H CH CHCH₃ 288 CH₂CH═CH₂ CH₃ CH₃ H H CH CH CH₃ 289 CH₂CH₂CH₃ CH₃ CH₃ H H CH CHCH₃ 290 (s)(CH₂)₃ H H H CH CH CH₃ 291 (s)(CH₂)₄ H H H CH CH CH₃ 292rac(CH₂)₃ H H H CH CH CH₃ 293 rac(CH₂)₄ H H H CH CH CH₃ 294 (R)(CH₂)₃ HH H CH CH CH₃ 295 (R)(CH₂)₄ H H H CH CH CH₃ 296 H H H H H N CH CH(CH₃)₂297 CH₃ H H H H N CH CH(CH₃)₂ 298 CH₂CH₃ H H H H N CH CH(CH₃)₂ 299CH₂CH═CH₂ H H H H N CH CH(CH₃)₂ 300 CH₂-c-C₃H₅ H H H H N CH CH(CH₃)₂ 301CH₂CH₂CH₃ H H H H N CH CH(CH₃)₂ 302 H (s)CH₃ H H H N CH CH(CH₃)₂ 303 CH₃(s)CH₃ H H H N CH CH(CH₃)₂ 304 CH₂CH₃ (s)CH₃ H H H N CH CH(CH₃)₂ 305CH₂CH═CH₂ (s)CH₃ H H H N CH CH(CH₃)₂ 306 CH₂-c-C₃H₅ (s)CH₃ H H H N CHCH(CH₃)₂ 307 CH₂CH₂CH₃ (s)CH₃ H H H N CH CH(CH₃)₂ 308 CH₂CH═CH₂ rac-CH₃H H H N CH CH(CH₃)₂ 309 CH₂CH₂CH₃ rac-CH₃ H H H N CH CH(CH₃)₂ 310 CH₂CH₃(R)CH₃ H H H N CH CH(CH₃)₂ 311 CH₂CH═CH₂ (R)CH₃ H H H N CH CH(CH₃)₂ 312CH₂-c-C₃H₅ (R)CH₃ H H H N CH CH(CH₃)₂ 313 CH₂CH₂CH₃ (R)CH₃ H H H N CHCH(CH₃)₂ 314 (s)(CH₂)₃ H H H N CH CH(CH₃)₂ 315 (s)(CH₂)₄ H H H N CHCH(CH₃)₂ 316 rac(CH₂)₃ H H H N CH CH(CH₃)₂ 317 rac(CH₂)₄ H H H N CHCH(CH₃)₂ 318 (R)(CH₂)₃ H H H N CH CH(CH₃)₂ 319 (R)(CH₂)₄ H H H N CHCH(CH₃)₂ 320 H H H H H N CH CH═CH₂ 321 CH₃ H H H H N CH CH═CH₂ 322CH₂CH₃ H H H H N CH CH═CH₂ 323 CH₂CH═CH₂ H H H H N CH CH═CH₂ 324CH₂-c-C₃H₅ H H H H N CH CH═CH₂ 325 CH₂CH₂CH₃ H H H H N CH CH═CH₂ 326 H(s)CH₃ H H H N CH CH═CH₂ 327 CH₃ (s)CH₃ H H H N CH CH═CH₂ 328 CH₂CH₃(s)CH₃ H H H N CH CH═CH₂ 329 CH₂CH═CH₂ (s)CH₃ H H H N CH CH═CH₂ 330CH₂-c-C₃H₅ (s)CH₃ H H H N CH CH═CH₂ 331 CH₂CH₂CH₃ (s)CH₃ H H H N CHCH═CH₂ 332 CH₂CH═CH₂ (R)CH₃ H H H N CH CH═CH₂ 333 CH₂CH₂CH₃ (R)CH₃ H H HN CH CH═CH₂ 334 CH₂CH═CH₂ rac-CH₃ H H H N CH CH═CH₂ 335 CH₂CH₂CH₃rac-CH₃ H H H N CH CH═CH₂ 336 H H H H H N CH c-C₃H₅ 337 CH₃ H H H H N CHc-C₃H₅ 338 CH₂CH₃ H H H H N CH c-C₃H₅ 339 CH₂CH═CH₂ H H H H N CH c-C₃H₅340 CH₂-c-C₃H₅ H H H H N CH c-C₃H₅ 341 CH₂CH₂CH₃ H H H H N CH c-C₃H₅ 342H (s)CH₃ H H H N CH c-C₃H₅ 343 CH₃ (s)CH₃ H H H N CH c-C₃H₅ 344 CH₂CH₃(s)CH₃ H H H N CH c-C₃H₅ 345 CH₂CH═CH₂ (s)CH₃ H H H N CH c-C₃H₅ 346CH₂-c-C₃H₅ (s)CH₃ H H H N CH c-C₃H₅ 347 CH₂CH₂CH₃ (s)CH₃ H H H N CHc-C₃H₅ 348 CH₂CH₃ (R)CH₃ H H H N CH c-C₃H₅ 349 CH₂CH═CH₂ (R)CH₃ H H H NCH c-C₃H₅ 350 CH₂CH₂CH₃ (R)CH₃ H H H N CH c-C₃H₅ 351 CH₂CH═CH₂ rac-CH₃ HH H N CH c-C₃H₅ 352 CH₂CH₂CH₃ rac-CH₃ H H H N CH c-C₃H₅ 353 H H H H H NCH CH₃ 354 CH₃ H H H H N CH CH₃ 355 CH₂CH₃ H H H H N CH CH₃ 356CH₂CH═CH₂ H H H H N CH CH₃ 357 CH₂-c-C₃H₅ H H H H N CH CH₃ 358 CH₂CH₂CH₃H H H H N CH CH₃ 359 H (s)CH₃ H H H N CH CH₃ 360 CH₃ (s)CH₃ H H H N CHCH₃ 361 CH₂CH₃ (s)CH₃ H H H N CH CH₃ 362 CH₂CH═CH₂ (s)CH₃ H H H N CH CH₃363 CH₂-c-C₃H₅ (s)CH₃ H H H N CH CH₃ 364 CH₂CH₂CH₃ (s)CH₃ H H H N CH CH₃365 CH₂CH═CH₂ (R)CH₃ H H H N CH CH₃ 366 CH₂CH₂CH₃ (R)CH₃ H H H N CH CH₃367 CH₂CH═CH₂ rac-CH₃ H H H N CH CH₃ 368 CH₂CH₂CH₃ rac-CH₃ H H H N CHCH₃ 369 H H H H H N CH CF₃ 370 CH₃ H H H H N CH CF₃ 371 CH₂CH₃ H H H H NCH CF₃ 372 CH₂CH═CH₂ H H H H N CH CF₃ 373 CH₂-c-C₃H₅ H H H H N CH CF₃374 CH₂CH₂CH₃ H H H H N CH CF₃ 375 H (s)CH₃ H H H N CH CF₃ 376 CH₃(s)CH₃ H H H N CH CF₃ 377 CH₂CH₃ (s)CH₃ H H H N CH CF₃ 378 CH₂CH═CH₂(s)CH₃ H H H N CH CF₃ 379 CH₂-c-C₃H₅ (s)CH₃ H H H N CH CF₃ 380 CH₂CH₂CH₃(s)CH₃ H H H N CH CF₃ 381 CH₂CH═CH₂ (R)CH₃ H H H N CH CF₃ 382 CH₂CH₂CH₃(R)CH₃ H H H N CH CF₃ 383 CH₂CH═CH₂ rac-CH₃ H H H N CH CF₃ 384 CH₂CH₂CH₃rac-CH₃ H H H N CH CF₃ 385 H H H H H CH N CH(CH₃)₂ 386 CH₃ H H H H CH NCH(CH₃)₂ 387 CH₂CH₃ H H H H CH N CH(CH₃)₂ 388 CH₂CH═CH₂ H H H H CH NCH(CH₃)₂ 389 CH₂-c-C₃H₅ H H H H CH N CH(CH₃)₂ 390 CH₂CH₂CH₃ H H H H CH NCH(CH₃)₂ 391 H (s)CH₃ H H H CH N CH(CH₃)₂ 392 CH₃ (s)CH₃ H H H CH NCH(CH₃)₂ 393 CH₂CH₃ (s)CH₃ H H H CH N CH(CH₃)₂ 394 CH₂CH═CH₂ (s)CH₃ H HH CH N CH(CH₃)₂ 395 CH₂-c-C₃H₅ (s)CH₃ H H H CH N CH(CH₃)₂ 396 CH₂CH₂CH₃(s)CH₃ H H H CH N CH(CH₃)₂ 397 CH₂CH═CH₂ rac-CH₃ H H H CH N CH(CH₃)₂ 398CH₂CH₂CH₃ rac-CH₃ H H H CH N CH(CH₃)₂ 399 CH₂CH₃ (R)CH₃ H H H CH NCH(CH₃)₂ 400 CH₂CH═CH₂ (R)CH₃ H H H CH N CH(CH₃)₂ 401 CH₂-c-C₃H₅ (R)CH₃H H H CH N CH(CH₃)₂ 402 CH₂CH₂CH₃ (R)CH₃ H H H CH N CH(CH₃)₂ 403 H H H HH CH N CH═CH₂ 404 CH₃ H H H H CH N CH═CH₂ 405 CH₂CH₃ H H H H CH N CH═CH₂406 CH₂CH═CH₂ H H H H CH N CH═CH₂ 407 CH₂-c-C₃H₅ H H H H CH N CH═CH₂ 408CH₂CH₂CH₃ H H H H CH N CH═CH₂ 409 H (s)CH₃ H H H CH N CH═CH₂ 410 CH₃(s)CH₃ H H H CH N CH═CH₂ 411 CH₂CH₃ (s)CH₃ H H H CH N CH═CH₂ 412CH₂CH═CH₂ (s)CH₃ H H H CH N CH═CH₂ 413 CH₂-c-C₃H₅ (s)CH₃ H H H CH NCH═CH₂ 414 CH₂CH₂CH₃ (s)CH₃ H H H CH N CH═CH₂ 415 CH₂CH═CH₂ rac-CH₃ H HH CH N CH═CH₂ 416 CH₂CH₂CH₃ rac-CH₃ H H H CH N CH═CH₂ 417 CH₂CH₃ (R)CH₃H H H CH N CH═CH₂ 418 CH₂CH═CH₂ (R)CH₃ H H H CH N CH═CH₂ 419 CH₂-c-C₃H₅(R)CH₃ H H H CH N CH═CH₂ 420 CH₂CH₂CH₃ (R)CH₃ H H H CH N CH═CH₂ 421 H HH H H CH N c-C₃H₅ 422 CH₃ H H H H CH N c-C₃H₅ 423 CH₂CH₃ H H H H CH Nc-C₃H₅ 424 CH₂CH═CH₂ H H H H CH N c-C₃H₅ 425 CH₂-c-C₃H₅ H H H H CH Nc-C₃H₅ 426 CH₂CH₂CH₃ H H H H CH N c-C₃H₅ 427 H (s)CH₃ H H H CH N c-C₃H₅428 CH₃ (s)CH₃ H H H CH N c-C₃H₅ 429 CH₂CH₃ (s)CH₃ H H H CH N c-C₃H₅ 430CH₂CH═CH₂ (s)CH₃ H H H CH N c-C₃H₅ 431 CH₂-c-C₃H₅ (s)CH₃ H H H CH Nc-C₃H₅ 432 CH₂CH₂CH₃ (s)CH₃ H H H CH N c-C₃H₅ 433 CH₂CH═CH₂ rac-CH₃ H HH CH N c-C₃H₅ 434 CH₂CH₂CH₃ rac-CH₃ H H H CH N c-C₃H₅ 435 CH₂CH₃ (R)CH₃H H H CH N c-C₃H₅ 436 CH₂CH═CH₂ (R)CH₃ H H H CH N c-C₃H₅ 437 CH₂-c-C₃H₅(R)CH₃ H H H CH N c-C₃H₅ 438 CH₂CH₂CH₃ (R)CH₃ H H H CH N c-C₃H₅ 439 H HH H H CH N CH₃ 440 CH₃ H H H H CH N CH₃ 441 CH₂CH₃ H H H H CH N CH₃ 442CH₂CH═CH₂ H H H H CH N CH₃ 443 CH₂-c-C₃H₅ H H H H CH N CH₃ 444 CH₂CH₂CH₃H H H H CH N CH₃ 445 H (s)CH₃ H H H CH N CH₃ 446 CH₃ (s)CH₃ H H H CH NCH₃ 447 CH₂CH₃ (s)CH₃ H H H CH N CH₃ 448 CH₂CH═CH₂ (s)CH₃ H H H CH N CH₃449 CH₂-c-C₃H₅ (s)CH₃ H H H CH N CH₃ 450 CH₂CH₂CH₃ (s)CH₃ H H H CH N CH₃451 CH₂CH═CH₂ rac-CH₃ H H H CH N CH₃ 452 CH₂CH₂CH₃ rac-CH₃ H H H CH NCH₃ 453 CH₂CH₃ (R)CH₃ H H H CH N CH₃ 454 CH₂CH═CH₂ (R)CH₃ H H H CH N CH₃455 CH₂-c-C₃H₅ (R)CH₃ H H H CH N CH₃ 456 CH₂CH₂CH₃ (R)CH₃ H H H CH N CH₃457 H H H H H CH N CF₃ 458 CH₃ H H H H CH N CF₃ 459 CH₂CH₃ H H H H CH NCF₃ 460 CH₂CH═CH₂ H H H H CH N CF₃ 461 CH₂-c-C₃H₅ H H H H CH N CF₃ 462CH₂CH₂CH₃ H H H H CH N CF₃ 463 H (s)CH₃ H H H CH N CF₃ 464 CH₃ (s)CH₃ HH H CH N CF₃ 465 CH₂CH₃ (s)CH₃ H H H CH N CF₃ 466 CH₂CH═CH₂ (s)CH₃ H H HCH N CF₃ 467 CH₂-c-C₃H₅ (s)CH₃ H H H CH N CF₃ 468 CH₂CH₂CH₃ (s)CH₃ H H HCH N CF₃ 469 CH₂CH₃ (R)CH₃ H H H CH N CF₃ 470 CH₂CH═CH₂ (R)CH₃ H H H CHN CF₃ 471 CH₂-c-C₃H₅ (R)CH₃ H H H CH N CF₃ 472 CH₂CH₂CH₃ (R)CH₃ H H H CHN CF₃ 473 CH₂CH═CH₂ rac-CH₃ H H H CH N CF₃ 474 CH₂CH₂CH₃ rac-CH₃ H H HCH N CF₃ 475 H H H H CH₃ CH CH CH(CH₃)₂ 476 CH₃ H H H CH₃ CH CH CH(CH₃)₂477 CH₂CH₃ H H H CH₃ CH CH CH(CH₃)₂ 478 CH₂CH═CH₂ H H H CH₃ CH CHCH(CH₃)₂ 479 CH₂-c-C₃H₅ H H H CH₃ CH CH CH(CH₃)₂ 480 CH₂CH₂CH₃ H H H CH₃CH CH CH(CH₃)₂ 481 H (s)CH₃ H H CH₃ CH CH CH(CH₃)₂ 482 CH₃ (s)CH₃ H HCH₃ CH CH CH(CH₃)₂ 483 CH₂CH₃ (s)CH₃ H H CH₃ CH CH CH(CH₃)₂ 484CH₂CH═CH₂ (s)CH₃ H H CH₃ CH CH CH(CH₃)₂ 485 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ CHCH CH(CH₃)₂ 486 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH CH CH(CH₃)₂ 487 CH₃ rac-CH₃H H CH₃ CH CH CH(CH₃)₂ 488 CH₂CH═CH₂ rac-CH₃ H H CH₃ CH CH CH(CH₃)₂ 489CH₂-c-C₃H₅ rac-CH₃ H H CH₃ CH CH CH(CH₃)₂ 490 CH₂CH₂CH₃ rac-CH₃ H H CH₃CH CH CH(CH₃)₂ 491 CH₃ (R)CH₃ H H CH₃ CH CH CH(CH₃)₂ 492 CH₂CH═CH₂(R)CH₃ H H CH₃ CH CH CH(CH₃)₂ 493 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH CHCH(CH₃)₂ 494 CH₂CH₂CH₃ (R)CH₃ H H CH₃ CH CH CH(CH₃)₂ 495 CH₃ H CH₃ H CH₃CH CH CH(CH₃)₂ 496 CH₂CH═CH₂ H CH₃ H CH₃ CH CH CH(CH₃)₂ 497 CH₂-c-C₃H₅ HCH₃ H CH₃ CH CH CH(CH₃)₂ 498 CH₂CH₂CH₃ H CH₃ H CH₃ CH CH CH(CH₃)₂ 499CH₃ CH₃ H CH₃ CH₃ CH CH CH(CH₃)₂ 500 CH₂CH═CH₂ CH₃ H CH₃ CH₃ CH CHCH(CH₃)₂ 501 CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ CH CH CH(CH₃)₂ 502 CH₂CH₂CH₃ CH₃ HCH₃ CH₃ CH CH CH(CH₃)₂ 503 CH₃ CH₃ CH₃ H CH₃ CH CH CH(CH₃)₂ 504CH₂CH═CH₂ CH₃ CH₃ H CH₃ CH CH CH(CH₃)₂ 505 CH₂-c-C₃H₅ CH₃ CH₃ H CH₃ CHCH CH(CH₃)₂ 506 CH₂CH₂CH₃ CH₃ CH₃ H CH₃ CH CH CH(CH₃)₂ 507 (S)(CH₂)₃ H HCH₃ CH CH CH(CH₃)₂ 508 (S)(CH₂)₄ H H CH₃ CH CH CH(CH₃)₂ 509 rac(CH₂)₃ HH CH₃ CH CH CH(CH₃)₂ 510 rac(CH₂)₄ H H CH₃ CH CH CH(CH₃)₂ 511 (R)(CH₂)₃H H CH₃ CH CH CH(CH₃)₂ 512 (R)(CH₂)₄ H H CH₃ CH CH CH(CH₃)₂ 513CH₂CH═CH₂ H H H CH₃ C—Cl CH CH(CH₃)₂ 514 CH₂-c-C₃H₅ H H H CH₃ C—Cl CHCH(CH₃)₂ 515 CH₂CH₂CH₃ H H H CH₃ C—Cl CH CH(CH₃)₂ 516 CH₂CH═CH₂ (s)CH₃ HH CH₃ C—Cl CH CH(CH₃)₂ 517 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ C—Cl CH CH(CH₃)₂518 CH₂CH₃ (s)CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 519 CH₂CH₂CH₃ (s)CH₃ H H CH₃C—Cl CH CH(CH₃)₂ 520 CH₂CH═CH₂ rac-CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 521CH₂-c-C₃H₅ rac-CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 522 CH₂CH₃ rac-CH₃ H H CH₃C—Cl CH CH(CH₃)₂ 523 CH₂CH₂CH₃ rac-CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 524CH₂CH═CH₂ (R)CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 525 CH₂-c-C₃H₅ (R)CH₃ H H CH₃C—Cl CH CH(CH₃)₂ 526 CH₂CH₂CH₃ (R)CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 527CH₂CH₃ (R)CH₃ H H CH₃ C—Cl CH CH(CH₃)₂ 528 CH₂CH═CH₂ H CH₃ H CH₃ C—Cl CHCH(CH₃)₂ 529 CH₂-c-C₃H₅ H CH₃ H CH₃ C—Cl CH CH(CH₃)₂ 530 CH₂CH₂CH₃ H CH₃H CH₃ C—Cl CH CH(CH₃)₂ 531 CH₂CH═CH₂ CH₃ H CH₃ CH₃ C—Cl CH CH(CH₃)₂ 532CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ C—Cl CH CH(CH₃)₂ 533 CH₂CH₂CH₃ CH₃ H CH₃ CH₃C—Cl CH CH(CH₃)₂ 534 CH₂CH═CH₂ CH₃ CH₃ H CH₃ C—Cl CH CH(CH₃)₂ 535CH₂-c-C₃H₅ CH₃ CH₃ H CH₃ C—Cl CH CH(CH₃)₂ 536 CH₂CH₂CH₃ CH₃ CH₃ H CH₃C—Cl CH CH(CH₃)₂ 537 (CH₂)₃ H H CH₃ C—Cl CH CH(CH₃)₂ 538 (CH₂)₄ H H CH₃C—Cl CH CH(CH₃)₂ 539 CH₂CH═CH₂ H H H CH₃ CH C—Cl CH(CH₃)₂ 540 CH₂-c-C₃H₅H H H CH₃ CH C—Cl CH(CH₃)₂ 541 CH₂CH₂CH₃ H H H CH₃ CH C—Cl CH(CH₃)₂ 542CH₂CH═CH₂ (s)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 543 CH₂-c-C₃H₅ (s)CH₃ H H CH₃CH C—Cl CH(CH₃)₂ 544 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 545CH₂CH₃ (s)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 546 CH₂CH═CH₂ rac-CH₃ H H CH₃ CHC—Cl CH(CH₃)₂ 547 CH₂-c-C₃H₅ rac-CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 548 CH₂CH₃rac-CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 549 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CH C—ClCH(CH₃)₂ 550 CH₂CH═CH₂ (R)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 551 CH₂-c-C₃H₅(R)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 552 CH₂CH₃ (R)CH₃ H H CH₃ CH C—ClCH(CH₃)₂ 553 CH₂CH₂CH₃ (R)CH₃ H H CH₃ CH C—Cl CH(CH₃)₂ 554 CH₂CH═CH₂ HCH₃ H CH₃ CH C—Cl CH(CH₃)₂ 555 CH₂-c-C₃H₅ H CH₃ H CH₃ CH C—Cl CH(CH₃)₂556 CH₂CH₂CH₃ H CH₃ H CH₃ CH C—Cl CH(CH₃)₂ 557 CH₂CH═CH₂ CH₃ H CH₃ CH₃CH C—Cl CH(CH₃)₂ 558 CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ CH C—Cl CH(CH₃)₂ 559CH₂CH₂CH₃ CH₃ H CH₃ CH₃ CH C—Cl CH(CH₃)₂ 560 CH₂CH═CH₂ CH₃ CH₃ H CH₃ CHC—Cl CH(CH₃)₂ 561 CH₂-c-C₃H₅ CH₃ CH₃ H CH₃ CH C—Cl CH(CH₃)₂ 562CH₂CH₂CH₃ CH₃ CH₃ H CH₃ CH C—Cl CH(CH₃)₂ 563 (CH₂)₃ H H CH₃ CH C—ClCH(CH₃)₂ 564 (CH₂)₄ H H CH₃ CH C—Cl CH(CH₃)₂ 565 CH₂CH═CH₂ H H H CH₃C—CH₃ CH CH(CH₃)₂ 566 CH₂-c-C₃H₅ H H H CH₃ C—CH₃ CH CH(CH₃)₂ 567CH₂CH₂CH₃ H H H CH₃ C—CH₃ CH CH(CH₃)₂ 568 CH₂CH═CH₂ (s)CH₃ H H CH₃ C—CH₃CH CH(CH₃)₂ 569 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 570CH₂CH₂CH₃ (s)CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 571 CH₂CH═CH₂ rac-CH₃ H H CH₃C—CH₃ CH CH(CH₃)₂ 572 CH₂-c-C₃H₅ rac-CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 573CH₂CH₂CH₃ rac-CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 574 CH₂CH═CH₂ (R)CH₃ H H CH₃C—CH₃ CH CH(CH₃)₂ 575 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 576CH₂CH₂CH₃ (R)CH₃ H H CH₃ C—CH₃ CH CH(CH₃)₂ 577 CH₂CH═CH₂ H CH₃ H CH₃C—CH₃ CH CH(CH₃)₂ 578 CH₂-c-C₃H₅ H CH₃ H CH₃ C—CH₃ CH CH(CH₃)₂ 579CH₂CH₂CH₃ H CH₃ H CH₃ C—CH₃ CH CH(CH₃)₂ 580 CH₂CH═CH₂ CH₃ H CH₃ CH₃C—CH₃ CH CH(CH₃)₂ 581 CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ C—CH₃ CH CH(CH₃)₂ 582CH₂CH₂CH₃ CH₃ H CH₃ CH₃ C—CH₃ CH CH(CH₃)₂ 583 CH₂CH═CH₂ CH₃ CH₃ H CH₃C—CH₃ CH CH(CH₃)₂ 584 CH₂-c-C₃H₅ CH₃ CH₃ H CH₃ C—CH₃ CH CH(CH₃)₂ 585CH₂CH₂CH₃ CH₃ CH₃ H CH₃ C—CH₃ CH CH(CH₃)₂ 586 (CH₂)₃ H H CH₃ C—CH₃ CHCH(CH₃)₂ 587 (CH₂)₄ H H CH₃ C—CH₃ CH CH(CH₃)₂ 588 CH₂CH═CH₂ H H H CH₃ CHC—CH₃ CH(CH₃)₂ 589 CH₂-c-C₃H₅ H H H CH₃ CH C—CH₃ CH(CH₃)₂ 590 CH₂CH₂CH₃H H H CH₃ CH C—CH₃ CH(CH₃)₂ 591 CH₂CH═CH₂ (s)CH₃ H H CH₃ CH C—CH₃CH(CH₃)₂ 592 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 593 CH₂CH₂CH₃(s)CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 594 CH₂CH═CH₂ rac-CH₃ H H CH₃ CH C—CH₃CH(CH₃)₂ 595 CH₂-c-C₃H₅ rac-CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 596 CH₂CH₂CH₃rac-CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 597 CH₂CH═CH₂ (R)CH₃ H H CH₃ CH C—CH₃CH(CH₃)₂ 598 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 599 CH₂CH₂CH₃(R)CH₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 600 CH₂CH═CH₂ H CH₃ H CH₃ CH C—CH₃CH(CH₃)₂ 601 CH₂-c-C₃H₅ H CH₃ H CH₃ CH C—CH₃ CH(CH₃)₂ 602 CH₂CH₂CH₃ HCH₃ H CH₃ CH C—CH₃ CH(CH₃)₂ 603 CH₂CH═CH₂ CH₃ H CH₃ CH₃ CH C—CH₃CH(CH₃)₂ 604 CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ CH C—CH₃ CH(CH₃)₂ 605 CH₂CH₂CH₃CH₃ H CH₃ CH₃ CH C—CH₃ CH(CH₃)₂ 606 CH₂CH═CH₂ CH₃ CH₃ H CH₃ CH C—CH₃CH(CH₃)₂ 607 CH₂-c-C₃H₅ CH₃ CH₃ H CH₃ CH C—CH₃ CH(CH₃)₂ 608 CH₂CH₂CH₃CH₃ CH₃ H CH₃ CH C—CH₃ CH(CH₃)₂ 609 (CH₂)₃ H H CH₃ CH C—CH₃ CH(CH₃)₂ 610(CH₂)₄ H H CH₃ CH C—CH₃ CH(CH₃)₂ 611 H H H H CH₃ CH CH c-C₃H₅ 612 CH₃ HH H CH₃ CH CH c-C₃H₅ 613 CH₂CH₃ H H H CH₃ CH CH c-C₃H₅ 614 CH₂CH═CH₂ H HH CH₃ CH CH c-C₃H₅ 615 CH₂-c-C₃H₅ H H H CH₃ CH CH c-C₃H₅ 616 CH₂CH₂CH₃ HH H CH₃ CH CH c-C₃H₅ 617 H (s)CH₃ H H CH₃ CH CH c-C₃H₅ 618 CH₃ (s)CH₃ HH CH₃ CH CH c-C₃H₅ 619 CH₂CH₃ (s)CH₃ H H CH₃ CH CH c-C₃H₅ 620 CH₂CH═CH₂(s)CH₃ H H CH₃ CH CH c-C₃H₅ 621 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ CH CH c-C₃H₅622 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH CH c-C₃H₅ 623 CH₃ rac-CH₃ H H CH₃ CH CHc-C₃H₅ 624 CH₂CH═CH₂ rac-CH₃ H H CH₃ CH CH c-C₃H₅ 625 CH₂-c-C₃H₅ rac-CH₃H H CH₃ CH CH c-C₃H₅ 626 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CH CH c-C₃H₅ 627CH₂CH₃ (R)CH₃ H H CH₃ CH CH c-C₃H₅ 628 CH₂CH═CH₂ (R)CH₃ H H CH₃ CH CHc-C₃H₅ 629 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH CH c-C₃H₅ 630 CH₂CH₂CH₃ (R)CH₃ HH CH₃ CH CH c-C₃H₅ 631 CH₃ H CH₃ H CH₃ CH CH c-C₃H₅ 632 CH₂CH═CH₂ H CH₃H CH₃ CH CH c-C₃H₅ 633 CH₂-c-C₃H₅ H CH₃ H CH₃ CH CH c-C₃H₅ 634 CH₂CH₂CH₃H CH₃ H CH₃ CH CH c-C₃H₅ 635 CH₃ CH₃ H CH₃ CH₃ CH CH c-C₃H₅ 636CH₂CH═CH₂ CH₃ H CH₃ CH₃ CH CH c-C₃H₅ 637 CH₂-c-C₃H₅ CH₃ H CH₃ CH₃ CH CHc-C₃H₅ 638 CH₂CH₂CH₃ CH₃ H CH₃ CH₃ CH CH c-C₃H₅ 639 CH₃ CH₃ CH₃ H CH₃ CHCH c-C₃H₅ 640 CH₂CH═CH₂ CH₃ CH₃ H CH₃ CH CH c-C₃H₅ 641 CH₂-c-C₃H₅ CH₃CH₃ H CH₃ CH CH c-C₃H₅ 642 CH₂CH₂CH₃ CH₃ CH₃ H CH₃ CH CH c-C₃H₅ 643(s)(CH₂)₃ H H CH₃ CH CH c-C₃H₅ 644 (s)(CH₂)₄ H H CH₃ CH CH c-C₃H₅ 645rac(CH₂)₃ H H CH₃ CH CH c-C₃H₅ 646 rac(CH₂)₄ H H CH₃ CH CH c-C₃H₅ 647(R)(CH₂)₃ H H CH₃ CH CH c-C₃H₅ 648 (R)(CH₂)₄ H H CH₃ CH CH c-C₃H₅ 649CH₂CH═CH₂ H H H CH₃ CH C—Cl c-C₃H₅ 650 CH₂-c-C₃H₅ H H H CH₃ CH C—Clc-C₃H₅ 651 CH₂CH₂CH₃ H H H CH₃ CH C—Cl c-C₃H₅ 652 CH₂CH═CH₂ (s)CH₃ H HCH₃ CH C—Cl c-C₃H₅ 653 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ CH C—Cl c-C₃H₅ 654CH₂CH₃ (s)CH₃ H H CH₃ CH C—Cl c-C₃H₅ 655 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CHC—Cl c-C₃H₅ 656 CH₂CH═CH₂ rac-CH₃ H H CH₃ CH C—Cl c-C₃H₅ 657 CH₂-c-C₃H₅rac-CH₃ H H CH₃ CH C—Cl c-C₃H₅ 658 CH₂CH₃ rac-CH₃ H H CH₃ CH C—Cl c-C₃H₅659 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CH C—Cl c-C₃H₅ 660 CH₂CH═CH₂ (R)CH₃ H HCH₃ CH C—Cl c-C₃H₅ 661 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH C—Cl c-C₃H₅ 662CH₂CH₂CH₃ (R)CH₃ H H CH₃ CH C—Cl c-C₃H₅ 663 CH₂CH₃ (R)CH₃ H H CH₃ CHC—Cl c-C₃H₅ 664 CH₂CH═CH₂ H H H CH₃ CH C—CH₃ c-C₃H₅ 665 CH₂-c-C₃H₅ H H HCH₃ CH C—CH₃ c-C₃H₅ 666 CH₂CH₂CH₃ H H H CH₃ CH C—CH₃ c-C₃H₅ 667CH₂CH═CH₂ (s)CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 668 CH₂-c-C₃H₅ (s)CH₃ H H CH₃CH C—CH₃ c-C₃H₅ 669 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 670CH₂CH═CH₂ rac-CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 671 CH₂-c-C₃H₅ rac-CH₃ H H CH₃CH C—CH₃ c-C₃H₅ 672 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 673CH₂CH═CH₂ (R)CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 674 CH₂-c-C₃H₅ (R)CH₃ H H CH₃CH C—CH₃ c-C₃H₅ 675 CH₂CH₂CH₃ (R)CH₃ H H CH₃ CH C—CH₃ c-C₃H₅ 676CH₂CH═CH₂ H H H CH₃ C—Cl CH c-C₃H₅ 677 CH₂-c-C₃H₅ H H H CH₃ C—Cl CHc-C₃H₅ 678 CH₂CH₂CH₃ H H H CH₃ C—Cl CH c-C₃H₅ 679 CH₂CH═CH₂ (s)CH₃ H HCH₃ C—Cl CH c-C₃H₅ 680 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ C—Cl CH c-C₃H₅ 681CH₂CH₃ (s)CH₃ H H CH₃ C—Cl CH c-C₃H₅ 682 CH₂CH₂CH₃ (s)CH₃ H H CH₃ C—ClCH c-C₃H₅ 683 CH₂CH═CH₂ rac-CH₃ H H CH₃ C—Cl CH c-C₃H₅ 684 CH₂-c-C₃H₅rac-CH₃ H H CH₃ C—Cl CH c-C₃H₅ 685 CH₂CH₂CH₃ rac-CH₃ H H CH₃ C—Cl CHc-C₃H₅ 686 CH₂CH═CH₂ (R)CH₃ H H CH₃ C—Cl CH c-C₃H₅ 687 CH₂-c-C₃H₅ (R)CH₃H H CH₃ C—Cl CH c-C₃H₅ 688 CH₂CH₃ (R)CH₃ H H CH₃ C—Cl CH c-C₃H₅ 689CH₂CH₂CH₃ (R)CH₃ H H CH₃ C—Cl CH c-C₃H₅ 690 CH₂CH═CH₂ H H H CH₃ C—CH₃ CHc-C₃H₅ 691 CH₂-c-C₃H₅ H H H CH₃ C—CH₃ CH c-C₃H₅ 692 CH₂CH₂CH₃ H H H CH₃C—CH₃ CH c-C₃H₅ 693 CH₂CH═CH₂ (s)CH₃ H H CH₃ C—CH₃ CH c-C₃H₅ 694CH₂-c-C₃H₅ (s)CH₃ H H CH₃ C—CH₃ CH c-C₃H₅ 695 CH₂CH₂CH₃ (s)CH₃ H H CH₃C—CH₃ CH c-C₃H₅ 696 CH₂CH═CH₂ rac-CH₃ H H CH₃ C—CH₃ CH c-C₃H₅ 697CH₂-c-C₃H₅ rac-CH₃ H H CH₃ C—CH₃ CH c-C₃H₅ 698 CH₂CH₂CH₃ rac-CH₃ H H CH₃C—CH₃ CH c-C₃H₅ 699 CH₃ H H H CH₃ CH CH C₂H₅ 700 CH₂CH═CH₂ H H H CH₃ CHCH C₂H₅ 701 CH₂-c-C₃H₅ H H H CH₃ CH CH C₂H₅ 702 CH₂CH₂CH₃ H H H CH₃ CHCH C₂H₅ 703 CH₃ (s)CH₃ H H CH₃ CH CH C₂H₅ 704 CH₂CH═CH₂ (s)CH₃ H H CH₃CH CH C₂H₅ 705 CH₂-c-C₃H₅ (s)CH₃ H H CH₃ CH CH C₂H₅ 706 CH₂CH₃ (s)CH₃ HH CH₃ CH CH C₂H₅ 707 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH CH C₂H₅ 708 CH₂CH═CH₂rac-CH₃ H H CH₃ CH CH C₂H₅ 709 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CH CH C₂H₅ 710CH₃ (R)CH₃ H H CH₃ CH CH C₂H₅ 711 CH₂CH═CH₂ (R)CH₃ H H CH₃ CH CH C₂H₅712 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH CH C₂H₅ 713 CH₂CH═CH₂ H CH₃ H CH₃ CH CHC₂H₅ 714 CH₂CH₂CH₃ H CH₃ H CH₃ CH CH C₂H₅ 715 CH₂CH═CH₂ CH₃ H CH₃ CH₃ CHCH C₂H₅ 716 CH₂CH₂CH₃ CH₃ H CH₃ CH₃ CH CH C₂H₅ 717 CH₂CH═CH₂ CH₃ CH₃ HCH₃ CH CH C₂H₅ 718 CH₂CH₂CH₃ CH₃ CH₃ H CH₃ CH CH C₂H₅ 719 (s)(CH₂)₃ H HCH₃ CH CH C₂H₅ 720 (s)(CH₂)₄ H H CH₃ CH CH C₂H₅ 721 rac(CH₂)₃ H H CH₃ CHCH C₂H₅ 722 rac(CH₂)₄ H H CH₃ CH CH C₂H₅ 723 H H H H CH₃ CH CH CH═CH₂724 CH₃ H H H CH₃ CH CH CH═CH₂ 725 CH₂CH₃ H H H CH₃ CH CH CH═CH₂ 726CH₂CH═CH₂ H H H CH₃ CH CH CH═CH₂ 727 CH₂-c-C₃H₅ H H H CH₃ CH CH CH═CH₂728 CH₂CH₂CH₃ H H H CH₃ CH CH CH═CH₂ 729 H (s)CH₃ H H CH₃ CH CH CH═CH₂730 CH₃ (s)CH₃ H H CH₃ CH CH CH═CH₂ 731 CH₂CH₃ (s)CH₃ H H CH₃ CH CHCH═CH₂ 732 CH₂CH═CH₂ (s)CH₃ H H CH₃ CH CH CH═CH₂ 733 CH₂-c-C₃H₅ (s)CH₃ HH CH₃ CH CH CH═CH₂ 734 CH₂CH₂CH₃ (s)CH₃ H H CH₃ CH CH CH═CH₂ 735CH₂CH═CH₂ rac-CH₃ H H CH₃ CH CH CH═CH₂ 736 CH₂CH₂CH₃ rac-CH₃ H H CH₃ CHCH CH═CH₂ 737 CH₂CH₃ (s)CH₃ H H CH₃ CH CH CH═CH₂ 738 CH₂CH═CH₂ (R)CH₃ HH CH₃ CH CH CH═CH₂ 739 CH₂-c-C₃H₅ (R)CH₃ H H CH₃ CH CH CH═CH₂ 740CH₂CH₂CH₃ (R)CH₃ H H CH₃ CH CH CH═CH₂ 741 CH₂CH═CH₂ H CH₃ H CH₃ CH CHCH═CH₂ 742 CH₂CH₂CH₃ H CH₃ H CH₃ CH CH CH═CH₂ 743 CH₂CH═CH₂ CH₃ H CH₃CH₃ CH CH CH═CH₂ 744 CH₂CH₂CH₃ CH₃ H CH₃ CH₃ CH CH CH═CH₂ 745 CH₂CH═CH₂CH₃ CH₃ H CH₃ CH CH CH═CH₂ 746 CH₂CH₂CH₃ CH₃ CH₃ H CH₃ CH CH CH═CH₂ 747(CH₂)₃ H H CH₃ CH CH CH═CH₂ 748 (CH₂)₄ H H CH₃ CH CH CH═CH₂ rac:racemate; (S): S configuration; (R) R configuration.

Other examples of compounds according to the invention are the compoundsof the general formulae Ia.3, Ib, Ic, Id, Ie and If:

in which R¹, R^(2a), R^(2c), R³, X, Y and R^(b) have the meaningsspecified in one line in Table 1.

Among the compounds of the general formula I, preference is also givento the compounds of the general formula Ig

in which n, k, R¹, R², R^(a), R^(b), A¹, A², A³, X and Y have themeanings given for formula Ia.

Among the compounds of the general formula I, preference is also givento the compounds of the general formula Ih

in which n, k, R¹, R², R^(a), R^(b), A¹, A², A³, X and Y have themeanings given for formula Ia.

Among the compounds of general formulae Ig and Ih, preference is givento the compounds of general formula Ig.1, Ig.2, Ih.1 and Ih.2

in which n, q, q′, X, Y, R¹, R², R^(a) and R^(b) have the meaningsmentioned previously for formulae Ia.1 and Ia.2 and R is CH₂ (compoundsIg.1 and Ig.2) or O (compounds Ih.1 or Ih.2).

Examples of compounds of the formula Ig.1 and Ih.1 are the compounds ofthe following general formulae Ig.1a, Ig.1b, Ig.1c, Ig.1d, Ig.1e, Ig.1f,Ig.1g, Ig.1h, Ig.1k, Ih.1a, Ih.1b, Ih.1c, Ih.1h, Ih.1e, Ih.1f, Ih.1g,Ih.1h and Ih.1k:

in which R¹, R^(2a), R^(2b), R^(2c), X, Y and R^(b) have the meaningsspecified in one of the lines 1 to 474 in Table 1.

Examples of compounds of the formula Ig.1 and Ih.1 are the compounds ofthe following general formulae Ig.2a, Ig.2b, Ig.2c, Ig.2d, Ig.2e, Ih.2a,Ih.2b, Ih.2c, Ih.2d and Ih.2e:

in which R¹, R^(2a), R^(2b), R^(2c), X, Y and R^(b) have the meaningsspecified in one of the lines 1 to 474 in Table 1.

The compounds I according to the invention are prepared in analogy withmethods known from the literature. An important approach to thecompounds according to the invention with R being O or N—R³ is offeredby the reaction of a hetarylcompound II with an arylsulfonic acidderivative III as depicted in scheme 1.

In scheme 1, n, R¹, R², R³, Ar and Q have the previously mentionedmeanings. R is O or N—R³. X is a nucleophilically displaceable leavinggroup, in particular a halogen atom and, especially, chlorine orbromine. The reaction depicted in scheme 1 takes place under thereaction conditions which are customary for preparing arylsulfonamidecompounds or arylsulfonic esters, respectively, and which are described,for example, in J. March, Advanced Organic Chemistry, 3^(rd) edition,John Wiley & Sons, New York, 1985 p 444 and the literature citedtherein, European J. Org. Chem. 2002 (13), pp. 2094-2108, Tetrahedron2001, 57 (27) pp. 5885-5895, Bioorganic and Medicinal Chemistry Letters,2000, 10(8), pp. 835-838 and Synthesis 2000 (1), pp. 103-108.

The reaction customarily takes place in an inert solvent, for example inan ether, such as diethyl ether, diisopropyl ether, methyl tert-butylether or tetrahydrofuran, a halohydrocarbon, such as dichloromethane, analiphatic or cycloaliphatic hydrocarbon, such as pentane, hexane orcyclohexane, or an aromatic hydrocarbon, such as toluene, xylene, cumeneand the like, or in a mixture of the abovementioned solvents.

The reaction of II with III is customarily carried out in the presenceof an auxiliary base. Suitable bases are inorganic bases, such assodiumcarbonate or potassiumcarbonate, or sodiumhydrogencarbonate orpotassiumhydrogencarbonate, and organic bases, for exampletrialkylamines, such as triethylamine, or pyridine compounds, such aspyridine, lutidine and the like. The latter compounds can at the sametime serve as solvents. The auxiliary base is customarily employed in atleast equimolar quantities, based on the amine compound II.

The compounds of the general formula II are known per se or, in case Ris N—R^(3a), can be prepared in the manner shown in schemes 2.

In scheme 2, n, R² and Q have the previously mentioned meanings. R^(1′)has the meanings different from hydrogen which are specified for R¹ oris a suitable protecting group. Suitable protecting groups aredisclosed, for example, in P. Kocienski, Protecting Groups,Thieme-Verlag, Stuttgart 2000, Chapter 6. Y is a nucleophilicallydisplaceable leaving group, in particular a halogen atom, e.g. chlorineor bromine, or an alkylsulfonyl group, e.g. methylsulfonyl.

The reaction depicted in step a) in scheme 2 takes place under thereaction conditions which are customary for a nucleophilic substitutionon an aromatic radical and which are described, for example, inTetrahedron 1999, 55(33), pp. 1024.3-10252, J. Med. Chem. 1997, 40(22),pp. 3679-3686 and Synthetic Communications, 1993, 23(5), pp. 591-599.Where appropriate, it can be advantageous to convert a ring nitrogenatom in the Q group into its N-oxide (see, for example, Angew. Chem.Int. Ed. Engl., 2002 41(11), pp. 1937-1940, J. Med. Chem. 1985, 28(2),pp. 248-252 and Tetrahedron Lett. 2002 43(17) pp. 3121-3123). Thisapproach has proved to be of value, in particular, for preparingcompounds I in which Q is a pyridin-2,4-diyl group. In connection withthe subsequent reduction of the nitro group in VI (step b), the N-oxidegroup is also reduced. For this, the reduction is carried out, forexample, in the presence of indium salts.

If 5-bromonitropyridine is used as compound V in step a) in accordancewith scheme 2, the coupling is also achieved under palladium catalysisin the presence of an auxiliary base, for example an alkali metalcarbonate such as cesium carbonate. Particularly suitable palladiumcatalysts in this connection are palladium(0) compounds or palladiumcompounds which are able to form a palladium(0) compound under reactionconditions, e.g. palladium dichloride,tetrakis(triphenylphosphine)palladium(0),tris(dibenzylideneacetone)dipalladium(0), advantageously in combinationwith phosphine ligands, e.g. triaryiphosphines, such astriphenylphosphine, trialkylphosphines, such as tributylphosphine, andcycloalkylphosphines, such as tricyclohexylphosphine, and, especially,using phosphine chelate ligands, such as2,2′-bis(diphenylphosphino)-1,1′-binaphthyl. The conditions which arerequired for reactions of this nature are described, for example, inTetrahedron Lett. 2001, 42(22), p. 3681 and Tetrahedron Lett. 2002,43(12), pp. 2171-2173.

In step b), the nitro group in VI is reduced to the NH₂ group in II.Subsequently, in step c), the NH₂ group can be converted into a—NR^(3′)H group, in which R^(3′) has the meanings different fromhydrogen which are specified for R³.

The reaction conditions which are required for step b) correspond to thecustomary conditions for reducing aromatic nitro groups which have beendescribed extensively in the literature (see, for example, J. March,Advanced Organic Chemistry, 3rd ed., J. Wiley & Sons, New-York, 1985, p.1183 and the literature cited in this reference).

The reduction is achieved, for example, by reacting the nitro compoundVII with a metal such as iron, zinc or tin under acidic reactionconditions, i.e. using nascent hydrogen, or using a complex hydride suchas lithium aluminum hydride or sodium borohydride, preferably in thepresence of transition metal compounds of nickel or cobalt such asNiCl₂(P(phenyl)₃)₂, or CoCl₂, (see Ono et al. Chem. Ind. (London), 1983p. 480), or using NaBH₂S₃ (see Lalancette et al. Can. J. Chem. 49, 1971,p. 2990), with it being possible to carry out these reductions,depending on the given reagent, in substance or in a solvent or diluent.Alternatively, the reduction of VI to II can be carried out withhydrogen in the presence of a transition metal catalyst, e.g. usinghydrogen in the presence of catalysts based on platinum, palladium,nickel, ruthenium or rhodium. The catalysts can contain the transitionmetal in elemental form or in the form of a complex compound, of a saltor of an oxide of the transition metal, with it being possible, for thepurpose of modifying the activity, to use customary coligands, e.g.organic phosphine compounds, such as triphenylphosphine,tricyclohexylphosphine or tri-n-butylphosphines or phosphites. Thecatalyst is customarily employed in quantities of from 0.001 to 1 molper mol of compound VI, calculated as catalyst metal. In a preferredvariant, the reduction is effected using tin(II) chloride in analogywith the methods described in Bioorganic and Medicinal ChemistryLetters; 2002, 12(15), pp. 1917-1919 and J. Med. Chem. 2002, 45(21), pp.4679-4688. The reaction of VI with tin(II) chloride is preferablycarried out in an inert organic solvent, preferably an alcohol such asmethanol, ethanol, isopropanol or butanol.

Reducing VI results in compounds II in which R³ is hydrogen. Customarymethods can then be used to react these compounds with an alkylatingagent R^(3′)—X, in which R^(3′) is C₁-C₄-alkyl and X is anucleophilically displaceable leaving group (e.g. halogen, such aschlorine, bromine or iodine), resulting in a compound II in whichR³=alkyl (step c). The reaction conditions which are required for thisare disclosed, for example, in WO 02/83652, Tetrahedron 2000, 56(38) pp.7553-7560 and Synlett. 2000 (4), pp. 475-480.

The compound I can also be prepared by the route depicted in scheme 3:

In scheme 3, n, R, R¹, R², Ar and Q have the previously mentionedmeanings. Y is a nucleophilically displaceable leaving group, inparticular a halogen atom, e.g. chlorine or bromine, or an alkylsulfonylgroup, e.g. methylsulfonyl. The reaction of VII with VIII, as depictedin scheme 3, takes place under the reaction conditions specified forscheme 2, step a). Compounds of the general formulae VII and VIII areknown or can be prepared in analogy with the methods known from theliterature. Compounds or the formula VIII, wherein R is N—R³ or anoxygen atom can be prepared by amidation of the correspondingaminocompound X-Q-NHR³ (or esterification of the correspondinghydroxycompound X-Q-OH) with a sulfonylhalide, especiall with asulfonylchloride of the formula Z—SO₂—Ar, wherein Z is halogen,especially chlorine or bromine, according to standard methods of organicchemistry (see e.g. J. March, Advanced Organic Chemistry, 3^(rd)edition, John Wiley & Sons, New York, 1985 p 444 and the literaturecited therein).

Compounds of general formula I, in which R¹ is an allyl group, can beconverted into compounds possessing different R¹ substituents using thesynthetic route shown in scheme 4.

In scheme 4, n, R, R², Ar and Q have the previously mentioned meanings.The elimination of the allyl group, as depicted in step a) in scheme 4,is achieved, for example, by reacting I [R¹=allyl] with an allyltrapping agent, such as mercaptobenzoic acid or 1,3-dimethylbarbituricacid, in the presence of catalytic quantities of palladium (0) compoundsor palladium compounds which are able to form a palladium(0) compoundunder reaction conditions, e.g. palladium dichloride,tetrakis(triphenylphosphine)-palladium(0) ortris(dibenzylideneacetone)dipalladium(0), advantageously in combinationwith phosphine ligands, e.g. triaryiphosphines, such astriphenylphosphine, trialkyiphosphines, such as tributylphosphine, andcycloalkylphosphines, such as tricyclohexylphosphine, and especiallywith phosphine chelate ligands, such as2,2′-bis(diphenylphosphino)-1,1′-binaphthyl or1,4-bis(diphenylphosphino)butane, using methods known from theliterature (with regard to eliminating N-allyl in the presence ofmercaptobenzoic acid, see WO 94/24088; with regard to eliminating in thepresence of 1,3-dimethylbarbituric acid, see J. Am. Chem. Soc. 2001, 123(28), pp. 6801-6808 and J. Org. Chem 2002, 67(11) pp. 3718-3723).Alternatively, the elimination of N-allyl, as depicted in scheme 4 stepa), can also be effected by reacting in the presence of rhodiumcompounds, such as tris(triphenylphosphine)chlororhodium(I), usingmethods known from the literature (see J. Chem. Soc., Perkin TransactionI: Organic and Bio-Organic Chemistry 1999 (21) pp. 3089-3104 andTetrahedron Asymmetry 1997, 8(20), pp. 3387-3391).

The resulting piperazine compound I [R¹═H] can then be reacted, in aknown manner, in the sense of an alkylation, with a compound R¹—X. Inthis compound, R¹ is C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl,C₁-C₄-alkoxy-C₁-C₄-alkyl or C₃-C₆-cycloalkyl-C₁-C₄-alkyl and X is anucleophilically displaceable leaving group, e.g. halogen,trifluoroacetate, alkylsulfonate, arylsulfonate, alkyl sulfate and thelike. The reaction conditions which are required for the alkylation instep b) have been adequately disclosed, e.g. in Bioorganic and MedicinalChemistry Lett. 2002, 12(7), pp. 2443-2446 and also 2002, 12(5), pp.1917-1919.

The conversion, as depicted in scheme 4, step b), of the piperazinecompound I [R¹═H] obtained in step a) can also be achieved, in the senseof a reductive amination, by reacting I [R¹═H] with a suitable ketone oraldehyde in the presence of a reducing agent, e.g. in the presence of aborohydride such as sodium borohydride, sodium cyanoborohydride orsodium triacetoxyborohydride. The skilled person is familiar with thereaction conditions which are required for a reductive amination, e.g.from Bioorganic and Medicinal Chemistry Lett. 2002, 12(5), pp. 795-798and 12(7) pp. 1269-1273.

The conversion, as depicted in scheme 4, step b), of the piperazinecompound I [R¹═H] obtained in step a) can also be achieved by successiveacylation and subsequent reduction of the acylation product, using themethod depicted in scheme 4a:

In scheme 4a, n, R, R², Ar and Q have the previously mentioned meanings.The acylation in step a) and the reduction in step b) are effected usingstandard methods of organic chemistry as are described, for example, inJ. March, Advanced Organic Chemistry, 3rd ed. J. Wiley & Sons, New York1985, p. 370 and 373 (acylation) and p. 1099 f. and in the literaturecited in this publication (with regard to acylation, see also Synth.Commun. 1986, 16, p. 267, and with regard to reduction, see also J.Heterocycl. Chem. 1979, 16, p. 1525).

In compounds of the general formula I which carry a halogen atom, inparticular bromine or iodine, on the aromatic radical Ar, the halogenatom can be converted into an alkyl, alkenyl, cycloalkyl, alkynyl orcycloalkylalkyl group using methods which are known per se. Theconversion is achieved by coupling the halo compound I to an alkyl-,alkenyl-, alkynyl-, cycloalkyl- or cycloalkylalkyl-boronic acid compoundunder the conditions of a Suzuki coupling as is described, for example,in Tetrahedron Lett. 2002, 43, pp. 6987-6990; Chem. Rev. 1995, 95, pp.2457-2483 and J. Org. Chem. 66(21) (2001), pp. 7124-7128.

Compounds of the formula I, wherein R is CR^(3a)R^(3b), can be alsoprepared by the synthetic route illustrated in scheme 5:

In scheme 5, n, R¹, R², Q, R^(3a), R^(3b) and Ar are as defined above. Lis a nucleophilically displaceable leaving group, in particular ahalogen atom such as chlorine or bromine or a sulfonate group, e.g. aC₁-C₄-alkylsulfonate such as methanesulfonate or an arylsulfonate suchbenzenesulfoante or tosylate (toluene sulfonate). L may also be OH, whenR^(3a), R^(3b) are different from hydrogen. The reaction depicted in thefirst step of scheme 5 takes place under the reaction conditions whichare customary for preparing arylsulfide compounds which are described,for example, in J. March, Advanced Organic Chemistry, 3^(rd) edition,John Wiley & Sons, New York, 1985 p 360 to 362, and in the literaturecited therein.

In the second step of scheme 5 the sulfide X obtained in the first stepis oxidized to the corresponding sulfone I (R═CR^(3a)R^(3b)) underreaction conditions which are customary for preparing arylsulfonecompounds from the corresponding arylsulfides and which are described,for example, in J. March, Advanced Organic Chemistry, 3^(rd) edition,John Wiley & Sons, New York, 1985 p 1089 f. and in the literature citedtherein.

The compounds of the formula IX are known in the art or can be preparedaccording to the method depicted in scheme 6:

In scheme 6, n, R¹, R², Q, R^(3a), R^(3b) and Ar are as defined above.Hal is halogen, especially chlorine, bromine or iodine. In step (a) ofscheme 6 the halogen compound XI is first metallized, i.e. convertedinto the corresponding lithium compound or magnesium compound bystandard methods of organic chemistry and the thus obtained metalcompound is reacted with an aldehyde or ketone to obtain the alcohol XII(see e.g. Tetrahedron 2003, 59 (24), 4303-4308). In step (b) he OH groupof XII is then converted into a suitable leaving group, e.g. into ahalogen atom by reaction with thionylhalide such as SOCl₂ orphosphorylhalide such as POCl₃, or into an alkylsulfonate orarylsulfonate by reaction with an alkylsulfonylhalide such asmethanesulfonylchloride or with an arylsulfonylhalide such astoluoenesulfonylchloride (see e.g. J. Med. Chem. 1985, 28 (12),1790-1796).

Alternatively the halogen compound XI is converted into the carbonylcompound XIII (step c, see e.g. J. Med. Chem. 1987, 30 (8), 1494-1497),which is then reduced (R^(3b)═H) or reacted with an alkylgrignardR^(3b)—Mg—X (X=halogen, e.g. Cl or Br) to obtain the alcohol XII (step(d), see e.g. J. Org. Chem. 2003, 68 (9), 3736-3738).

If not otherwise indicated, the above-described reactions are generallycarried out in a solvent at temperatures between room temperature andthe boiling temperature of the solvent employed. Alternatively, theactivation energy which is required for the reaction can be introducedinto the reaction mixture using microwaves, something which has provedto be of value, in particular, in the case of the reactions catalyzed bytransition metals (with regard to reactions using microwaves, seeTetrahedron 2001, 57, p. 9199 ff. p. 9225 ff. and also, in a generalmanner, “Microwaves in Organic Synthesis”, André Loupy (Ed.), Wiley-VCH2002.

Examples of solvents which can be used are ethers, such as diethylether, diisopropyl ether, methyl tert-butyl ether or tetrahydrofuran,aprotic polar solvent, such as dimethylformamide, dimethyl sulfoxide,dimethoxyethane, and acetonitrile, aromatic hydrocarbons, such astoluene and xylene, ketones, such as acetone or methyl ethyl ketone,halohydrocarbons, such as dichloromethane, trichloromethane anddichloroethane, esters, such as ethyl acetate and methyl butyrate,carboxylic acids, such as acetic acid or propionic acid, and alcohols,such as methanol, ethanol, n-propanol, isopropanol and butanol.

If desired, it is possible for a base to be present in order toneutralize protons which are released in the reactions. Suitable basesinclude inorganic bases, such as sodium carbonate, potassium carbonate,sodium hydrogen carbonate or potassium hydrogen carbonate, and, inaddition, alkoxides, such as sodium methoxide or sodium ethoxide, alkalimetal hydrides, such as sodium hydride, and also organometalliccompounds, such as butyllithium compounds or alkylmagnesium compounds,or organic nitrogen bases, such as triethylamine or pyridine. The lattercompounds can at the same time serve as solvents.

The crude product is isolated in a customary manner, for example byfiltering, distilling off the solvent or extracting from the reactionmixture, etc. The resulting compounds can be purified in a customarymanner, for example by means of recrystallizing from a solvent, by meansof chromatography or by means of converting into an acid addition salt.

The acid addition salts are prepared in a customary manner by mixing thefree base with a corresponding acid, where appropriate in solution in anorganic solvent, for example a lower alcohol, such as methanol, ethanolor propanol, an ether, such as methyl tert-butyl ether or diisopropylether, a ketone, such as acetone or methyl ethyl ketone, or an ester,such as ethyl acetate.

The compounds according to the invention of the formula I are highlyselective dopamine D₃ receptor ligands which, because of their lowaffinity for other receptors such as D₁ receptors, D₄ receptors,α1-adrenergic and/or α2-adrenergic receptors, muscarinergic receptors,histamine receptors, opiate receptors and, in particular, dopamine D₂receptors, give rise to fewer side-effects than do the classicneuroleptics, which are D₂ receptor antagonists.

The high affinity of the compounds according to the invention for D₃receptors is reflected in very low in-vitro K_(i) values of as a ruleless than 100 nM (nmol/l), in particular less than 50 nM and, inparticular, of less than 10 nM. The displacement of [¹²⁵I]-iodosulpridecan, for example, be used in receptor binding studies for determiningbinding affinities for D₃ receptors.

The selectivity K_(i)(D₂)/K_(i)(D₃) of the compounds according to theinvention is as a rule at least 10, preferably at least 30, even betterat least 50 and particularly advantageously at least 100. Thedisplacement of [³H]SCH23390, [¹²⁵I] iodosulpride or [¹²⁵I] spiperonecan be used, for example, for carrying out receptor binding studies onD₁, D₂ and D₄ receptors.

Because of their binding profile, the compounds can be used for treatingdiseases which respond to dopamine D₃ ligands, i.e. they are effectivefor treating those disturbances or diseases in which exerting aninfluence on (modulating) the dopamine D₃ receptors leads to animprovement in the clinical picture or to the disease being cured.Examples of these diseases are disturbances or diseases of the centralnervous system.

Disturbances or diseases of the central nervous system are understood asmeaning disturbances which affect the spinal chord and, in particular,the brain. Within the meaning of the invention, the term “disturbance”denotes anomalies which are as a rule regarded as being pathologicalconditions or functions and which can manifest themselves in the form ofparticular signs, symptoms and/or malfunctions. While the treatmentaccording to the invention can be directed toward individualdisturbances, i.e. anomalies or pathological conditions, it is alsopossible for several anomalies, which may be causatively linked to eachother, to be combined into patterns, i.e. syndromes, which can betreated in accordance with the invention.

The disturbances which can be treated in accordance with the inventionare, in particular, psychiatric and neurological disturbances. Thesedisturbances include, in particular, organic disturbances, includingsymptomatic disturbances, such as psychoses of the acute exogenousreaction type or attendant psychoses of organic or exogenous cause,e.g., in association with metabolic disturbances, infections andendocrinopathogies; endogenous psychoses, such as schizophrenia andschizotype and delusional disturbances; affective disturbances, such asdepressions, mania and/or manicdepressive conditions; and also mixedforms of the above-described disturbances; neurotic and somatoformdisturbances and also disturbances in association with stress;dissociative disturbances, e.g. loss of consciousness, clouding ofconsciousness, double consciousness and personality disturbances;disturbances in attention and waking/sleeping behavior, such asbehavioral disturbances and emotional disturbances whose onset lies inchildhood and youth, e.g. hyperactivity in children, intellectualdeficits, in particular attention disturbances (attention deficitdisorders), memory disturbances and cognitive disturbances, e.g.impaired learning and memory (impaired cognitive function), dementia,narcolepsy and sleep disturbances, e.g. restless legs syndrome;development disturbances; anxiety states, delirium; sexlifedisturbances, e.g. impotence in men; eating disturbances, e.g. anorexiaor bulimia; addiction; and other unspecified psychiatric disturbances.

The disturbances which can be treated in accordance with the inventionalso include Parkinson's disease and epilepsy and, in particular, theaffective disturbances connected thereto.

The addiction diseases include psychic disturbances and behavioraldisturbances which are caused by the abuse of psychotropic substances,such as pharmaceuticals or narcotics, and also other addiction diseases,such as addiction to gaming (impulse control disorders not elsewhereclassified). Examples of addictive substances are: opioids (e.g.morphine, heroin and codeine), cocaine; nicotine; alcohol; substanceswhich interact with the GABA chloride channel complex, sedatives,hypnotics and tranquilizers, for example benzodiazepines; LSD;cannabinoids; psychomotor stimulants, such as3,4-methylenedioxy-N-methylamphetamine (ecstasy); amphetamine andamphetamine-like substances such as methylphenidate and other stimulantsincluding caffeine. Addictive substances which come particularly intoconsideration are opioids, cocaine, amphetamine or amphetamine-likesubstances, nicotine and alcohol.

With regard to the treatment of addiction diseases, particularpreference is given to those compounds according to the invention of theformula I which themselves do not possess any psychotropic effect. Thiscan also be observed in a test using rats, which, after having beenadministered compounds which can be used in accordance with theinvention, reduce their self administration of psychotropic substances,for example cocaine.

According to another aspect of the present invention, the compoundsaccording to the invention are suitable for treating disturbances whosecauses can at least partially be attributed to an anomalous activity ofdopamine D₃ receptors.

According to another aspect of the present invention, the treatment isdirected, in particular, toward those disturbances which can beinfluenced, within the sense of an expedient medicinal treatment, by thebinding of preferably exogeneously administered binding partners(ligands) to dopamine D₃ receptors.

The diseases which can be treated with the compounds according to theinvention are frequently characterized by progressive development, i.e.the above-described conditions change over the course of time; as arule, the severity increases and conditions may possibly merge into eachother or other conditions may appear in addition to those which alreadyexist.

The compounds according to the invention can be used to treat a largenumber of signs, symptoms and/or malfunctions which are connected withthe disturbances of the central nervous system and, in particular, theabovementioned conditions. These signs, symptoms and/or malfunctionsinclude, for example, a disturbed relationship to reality, lack ofinsight and ability to meet customary social norms or the demands madeby life, changes in temperament, changes in individual drives, such ashunger, sleep, thirst, etc., and in mood, disturbances in the ability toobserve and combine, changes in personality, in particular emotionallability, hallucinations, ego-disturbances, distractedness, ambivalence,autism, depersonalization and false perceptions, delusional ideas,chanting speech, lack of synkinesia, short-step gait, flexed posture oftrunk and limbs, tremor, poverty of facial expression, monotonousspeech, depressions, apathy, impeded spontaneity and decisiveness,impoverished association ability, anxiety, nervous agitation,stammering, social phobia, panic disturbances, withdrawal symptoms inassociation with dependency, maniform syndromes, states of excitationand confusion, dysphoria, dyskinetic syndromes and tic disturbances,e.g. Huntington's chorea and Gilles-de-la-Tourette's syndrome, vertigosyndromes, e.g. peripheral positional, rotational and oscillatoryvertigo, melancholia, hysteria, hypochondria and the like.

Within the meaning of the invention, a treatment also includes apreventive treatment (prophylaxis), in particular as relapse prophylaxisor phase prophylaxis, as well as the treatment of acute or chronicsigns, symptoms and/or malfunctions. The treatment can be orientatedsymptomatically, for example as the suppression of symptoms. It can beeffected over a short period, be orientated over the medium term or canbe a long-term treatment, for example within the context of amaintenance therapy.

The compounds according to the invention are preferentially suitable fortreating diseases of the central nervous system, in particular fortreating affective disturbances; neurotic disturbances, stressdisturbances and somatoform disturbances and psychoses, and, inparticular, for treating schizophrenia and depression. Because of theirhigh selectivity with regard to the D₃ receptor, the compounds Iaccording to the invention are also suitable for treating disturbancesof kidney function, in particular disturbances of kidney function whichare caused by diabetes mellitus (see WO 00/67847) and, especially,diabetic nephropathy.

Within the context of the treatment, the use according to the inventionof the described compounds involves a method. In this method, aneffective quantity of one or more compounds, as a rule formulated inaccordance with pharmaceutical and veterinary practice, is administeredto the individual to be treated, preferably a mammal, in particular ahuman being, productive animal or domestic animal. Whether such atreatment is indicated, and in which form it is to take place, dependson the individual case and is subject to medical assessment (diagnosis)which takes into consideration signs, symptoms and/or malfunctions whichare present, the risks of developing particular signs, symptoms and/ormalfunctions, and other factors.

As a rule, the treatment is effected by means of single or repeateddaily administration, where appropriate together, or alternating, withother active compounds or active compound-containing preparations suchthat a daily dose of preferably from about 0.1 to 1000 mg/kg ofbodyweight, in the case of oral administration, or of from about 0.1 to100 mg/kg of bodyweight, in the case of parenteral administration, issupplied to an individual to be treated.

The invention also relates to the production of pharmaceuticalcompositions for treating an individual, preferably a mammal, inparticular a human being, productive animal or domestic animal. Thus,the ligands are customarily administered in the form of pharmaceuticalcompositions which comprise a pharmaceutically acceptable excipienttogether with at least one ligand according to the invention and, whereappropriate, other active compounds. These compositions can, forexample, be administered orally, rectally, transdermally,subcutaneously, intravenously, intramuscularly or intranasally.

Examples of suitable pharmaceutical formulations are solid medicinalforms, such as powders, granules, tablets, in particular film tablets,lozenges, sachets, cachets, sugar-coated tablets, capsules, such as hardgelatin capsules and soft gelatin capsules, suppositories or vaginalmedicinal forms, semisolid medicinal forms, such as ointments, creams,hydrogels, pastes or plasters, and also liquid medicinal forms, such assolutions, emulsions, in particular oil-in-water emulsions, suspensions,for example lotions, injection preparations and infusion preparations,and eyedrops and eardrops. Implanted release devices can also be usedfor administering inhibitors according to the invention. In addition, itis also possible to use liposomes or microspheres. When producing thecompositions, inhibitors according to the invention are usually mixed ordiluted with an excipient. Excipients can be solid, semisolid or liquidmaterials which serve as vehicles, carriers or medium for the activecompound.

Suitable excipients are listed in the specialist medicinal monographs.In addition, the formulations can comprise pharmaceutically acceptablecarriers or customary auxiliary substances, such as glidants; wettingagents; emulsifying and suspending agents; preservatives; antioxidants;antiirritants; chelating agents; coating auxiliaries; emulsionstabilizers; film formers; gel formers; odor masking agents; tastecorrigents; resin; hydrocolloids; solvents; solubilizers; neutralizingagents; diffusion accelerators; pigments; quaternary ammonium compounds;refatting and overfatting agents; raw materials for ointments, creams oroils; silicone derivatives; spreading auxiliaries; stabilizers;sterilants; suppository bases; tablet auxiliaries, such as binders,fillers, glidants, disintegrants or coatings; propellants; dryingagents; opacifiers; thickeners; waxes; plasticizers and white mineraloils. A formulation in this regard is based on specialist knowledge asdescribed, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe fürPharmazie, Kosmetik and angrenzende Gebiete [Encyclopedia of auxiliarysubstances for pharmacy, cosmetics and related fields], 4^(th) edition,Aulendorf: ECV-Editio-Kantor-Verlag, 1996.

The following examples serve to explain the invention without limitingit.

The magnetic nuclear resonance spectral properties (NMR) refer to thechemical shifts (δ) expressed in parts per million (ppm). The relativearea of the shifts in the ¹H NMR spectrum corresponds to the number ofhydrogen atoms for a particular functional type in the molecule. Thenature of the shift, as regards multiplicity, is indicated as singlet(s), broad singlet (s. br.), doublet (d), broad doublet (d br.), triplet(t), broad triplet (t br.), quartet (q), quintet (quint.) and multiplet(m).

PREPARATION EXAMPLES Example 1N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide1.1 1-Allyl-4-(5-nitropyridin-2-yl)piperazine

2.0 g (12.61 mmol) of 2-chloro-5-nitropyridine were dissolved in 8 ml ofdimethylformamide, and 3.49 g (25.23 mmol) of potassium carbonate wereadded. After that, a solution of 1.75 g (13.88 mmol) ofN-allylpiperazine in 2 ml of dimethylformamide was added slowly dropwiseto the reaction mixture (exothermic reaction). The reaction mixture wasthen stirred at room temperature for 2 hours. After the solvent had beenconcentrated down to dryness, the resulting residue was stirred up in100 ml of heptane. The precipitate which remained was filtered off withsuction. The filtrate was concentrated, resulting in 720 mg of the titlecompound. The precipitate which had been filtered off with suction wastreated with 150 ml of water and extracted three times with diethylether. The organic phase was washed with a saturated solution of sodiumchloride and dried over sodium sulfate. A further 2.24 g of the titlecompound were isolated after the solvent had been filtered andconcentrated down to dryness. The total yield of1-allyl-4-(5-nitropyridin-2-yl)piperazine was 2.96 g (95% of theory).

MS [m+1]: 249.

1.2 6-(4-Allylpiperazin-1-yl)pyridine-3-amine

2.2 g (8.86 mmol) of 1-allyl-4-(5-nitropyridin-2-yl)piperazine fromExample 1.1 were dissolved in 150 ml of methanol after which 18g (79.75mmol) of tin(II) chloride dihydrate were added and the mixture wasstirred at 70° C. for 4 hours. After the solvent had been evaporateddown to dryness, water was added to the residue. The aqueous reactionmixture was made alkaline with dilute sodium hydroxide solution and thenextracted with ethyl acetate. The solid which had precipitated out wasfiltered off. After that, the phases were separated and the aqueousphase was extracted in each case twice with ethyl acetate anddichloromethane. The combined organic phases were dried over sodiumsulfate. 1.74 g (90% of theory) of the title compound were obtainedafter the drying agent had been removed and the solvent had beenevaporated down to dryness.

MS [m+1]: 219.

1.3N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamide

1.4 g (7.97 mmol) of 6-(4-allylpiperazin-1-yl)pyridin-3-ylamine fromExample 1.2 and 1.74 g (7.97 mmol) of 4-isopropylbenzenesulfonylchloride were dissolved in 30 ml of tetrahydrofuran at room temperature.3.3 ml (23.91 mmol) of triethylamine were then added to this mixture.After that, the reaction mixture was stirred overnight at roomtemperature. After the solvent had been evaporated to dryness, water wasadded to the residue. The aqueous reaction mixture was made acid with 1Nhydrochloric acid and extracted twice with diethyl ether. After that,the aqueous phase was made alkaline (pH 9-10) with a 1N aqueous solutionof sodium hydroxide and then extracted twice with diethyl ether. Afterthe combined organic phases had been dried over sodium sulfate, thedrying agent had been filtered off and the solvent had been evaporateddown to dryness, the resulting residue was chromatographed on silica gelusing cyclohexane/ethyl acetate (45:55% to 100% ethyl acetate). Thefiltrate was evaporated down to dryness. The resulting residue wasthoroughly stirred in 10 ml of heptane, filtered off in suction anddried, with 1.93 g (61% of theory) of the title compound being obtained.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 7.7 (s, 1H); 7.6 (d, 2H); 7.4 (d, 1H);7.3 (d, 2H); 6.6 (d, 1H); 6.4 (bs, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5(m, 4H); 3.1 (m, 2H); 3.0 (m, 1H); 2.5 (m, 4H); 1.2 (d, 6H).

MS [m+1]: 401.

Example 2N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-propylbenzenesulfonamide

373 mg of the title compound were obtained in an analogous manner tothat described in Example 1.3 when starting with4-n-propylbenzenesulfonyl chloride.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 7.7 (m, 1H); 7.6 (m, 2H); 7.4 (d, 1H);7.3 (m, 2H); 6.6 (d, 1H); 6.3 (bs, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5(m, 4H); 3.1 (m, 2H); 2.6 (m, 2H); 2.5 (m, 4H); 1.7 (m, 2H); 0.9 (m,3H).

MS [m+1]: 401.

Example 3N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-butylbenzenesulfonamide

405 mg of the title compound were obtained in an analogous manner tothat described in Example 1.3 when starting with4-n-butylbenzenesulfonyl chloride.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 7.7 (m, 1H); 7.6 (m, 2H); 7.4 (d, 1H);7.3 (m, 2H); 6.6 (d, 1H); 6.2 (bs, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5(m, 4H); 3.0 (m, 2H); 2.7 (m, 2H); 2.5 (m, 4H); 1.6 (m, 2H); 1.4 (m,2H); 0.9 (m, 3H).

MS [m+1]: 415.

Example 4N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonamide

500 mg of the title compound were obtained in an analogous manner tothat described in Example 1.3 when starting with4-trifluoromethylbenzenesulfonyl chloride.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 7.9 (d, 2H); 7.8 (m, 3H); 7.3 (d, 1H);6.6 (d, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.5 (m, 4H); 3.1 (m, 2H); 2.5 (m,4H).

MS [m+1]: 427.

Example 5N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-ethylbenzenesulfonamidehydrochloride

The Example 1.3 was repeated with 4-ethylbenzenesulfonyl chloride beingused instead of 4-isopropylbenzenesulfonyl chloride. The resultingreaction product was converted into the hydrochloride with etherealhydrochloric acid, with 480 mg (please complete) of the title compoundbeing obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.5 (bs, 1H); 10.0 (s, 1H); 7.8 (d,2H); 7.6 (d, 2H); 7.4 (m, 3H); 6.9 (d, 1H); 6.0 (m, 1H); 5.5 (m, 2H);4.3 (m, 2H); 3.8 (m, 2H); 3.4 (m, 2H); 3.3 (m, 2H); 3.0 (m, 2H); 2.7 (m,2H); 1.2 (t, 3H).

MS [m+1]: 387 (free base).

Example 6N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonamidehydrochloride

Example 1.3 was repeated with 4-vinylbenzenesulfonyl chloride being usedinstead of 4-isopropylbenzenesulfonyl chloride. The resulting reactionproduct was converted into the hydrochloride with ethereal hydrochloricacid, with 300 mg of the title compound being obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.1 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (m, 4H); 7.3 (d, 1H); 6.9 (d, 1H); 6.8 (dd, 1H); 6.0 (m, 2H);5.5 (m, 3H); 4.3 (m, 2H); 3.8 (m, 2H); 3.4 (m, 2H); 3.2 (m, 2H); 3.0 (m,2H).

MS [m+1]: 385 (free base).

Example 7 4-Isopropyl-N-(6-piperazin-1-ylpyridin-3-yl)benzenesulfonamide

95 mg (0.1 mmol) of tris-(dibenzylideneacetone)dipalladium(0) and 44 mg(0.1 mmol) of 1,4-bis-(diphenylphosphino)butane were dissolved in 10 mlof tetrahydrofuran under an argon atmosphere. A solution composed of 1.1g (2.75 mmol) ofN-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidefrom Example 1.3 I in 3 ml of tetrahydrofuran was then added dropwise tothe reaction mixture. After that, a solution of 386 mg (2.5 mmol) of2-mercaptobenzoic acid in 2 ml of tetrahydrofuran was added dropwise tothe reaction mixture and the mixture was stirred at room temperature for90 minutes. A solution of a further 386 mg (2.5 mmol) of2-mercaptobenzoic acid in 2 ml of tetrahydrofuran was then addeddropwise to the reaction mixture. The reaction mixture was stirredovernight at room temperature and, after that, the solvent wasevaporated down to dryness. 150 ml of water were added to the resultingresidue, after which the mixture was made acid with 1N aqueoushydrochloric acid and extracted three times with diethyl ether. Theaqueous phase was then made alkaline, to pH>11, with a 1N aqueoussolution of sodium hydroxide and subsequently extracted three times withdichloromethane. After that, the aqueous phase was adjusted to pH 8-9,saturated with an aqueous solution of sodium chloride and, after that,extracted several times with dichloromethane. 840 mg (82% of theory) ofthe title compound were obtained after the combined organic phases hadbeen dried over sodium sulfate and the solvent had been filtered andevaporated down to dryness.

¹H-NMR (400 MHz, CDCl₃): δ [ppm] 7.7 (d, 1H); 7.6 (d, 2H); 7.4 (dd, 1H);7.3 (d, 2H); 6.6 (d, 1H); 3.5 (m, 4H); 3.0 (m, 5H); 1.2 (d, 6H).

MS [m+1]: 361.

Example 8N-{6-[4-(Cyclohexylmethyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesulfonamidehydrochloride

150 mg (0.42 mmol) of4-isopropyl-N-(6-piperazin-1-yl-pyridin-3-yl)-benzenesulfonamide fromExample 7 and 51 mg (0.46 mmol) of cyclohexanealdehyde were dissolved in5 ml of dichloromethane and 40 μl (0.62 mmol) of glacial acetic acidunder a nitrogen atmosphere. 133 mg (0.63 mmol) of sodiumtrisacetoxyborohydride were then added. The mixture was stirred at roomtemperature for 90 minutes and, after that, the solvent was evaporateddown to dryness. The resulting residue was taken up in water and thismixture was made to pH>11 with a 1N aqueous solution of sodiumhydroxide. After that, the aqueous reaction mixture was extracted withdiethyl ether. After the organic phase had been dried over sodiumsulfate and the solvent had been filtered and evaporated down todryness, the resulting residue was converted into the hydrochloride withethereal hydrochloric acid, resulting in 156 mg (76% of theory) of thetitle compound.

¹H-NMR (500 MHz, DMSO-d₆): δ [ppm] 10.4 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.2 (m, 2H);3.5 (m, 2H); 3.4 (m, 2H); 3.0 (m, 5H); 1.8 (m, 3H); 1.7 (m, 3H); 1.2 (m,9H); 1.0 (m, 2H).

MS [m+1]: 457 (free base).

The compounds of Examples 9 to 12 were prepared in an analogous manner.

Example 9N-[6-(4-Isobutylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

¹H-NMR (500 MHz, DMSO-d₆): δ [ppm] 10.4 (bs, 1H); 10.0 (s, 1H); 7.8 (m,1H); 7.6 (d, 2H); 7.5 (d, 2H); 7.4 (m, 1H); 6.9 (d, 1H); 4.2 (d, 2H);3.5 (d, 2H); 3.4 (m, 2H); 3.0 (m, 5H); 2.1 (m, 1H); 1.2 (d, 6H); 1.0 (d,6H).

MS [m+1]: 417 (free base).

Example 104-Isopropyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]benzenesulfonamide

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 7.7 (d, 1H); 7.6 (d, 2H); 7.4 (dd, 1H);7.3 (d, 2H); 6.6 (d, 1H); 3.5 (m, 4H); 3.0 (m, 1H); 2.5 (m, 4H); 2.3 (s,3H); 1.2 (d, 6H).

MS [m+1]: 375.

Example 11N-[6-(4-Ethylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

¹H-NMR (500 MHz, DMSO-d₆): δ [ppm] 10.4 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.3 (m, 2H);3.5 (m, 2H); 3.2 (m, 2H); 3.1 (m, 2H); 3.0 (m, 3H); 1.3 (m, 3H); 1.2 (d,6H).

MS [m+1]: 389 (free base).

Example 12N-{6-[4-(Cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesulfonamidehydrochloride

¹H-NMR (500 MHz, DMSO-d₆): δ [ppm] 10.8 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.3 (m, 2H);3.6 (m, 2H); 3.3 (m, 2H); 3.0 (m, 5H); 1.2 (d, 6H); 1.1 (m, 1H); 0.6 (m,2H); 0.4 (m, 2H).

MS [m+1]: 415 (free base)

Example 13N-[6-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride 13.1 3-Methyl-1-(5-nitropyridin-2-yl)piperazine

872 mg (6.31 mmol) of potassium carbonate were added to a solution of500 mg (3.15 mmol) of 2-chloro-5-nitropyridine in 7 ml ofdimethylformamide. After that, a solution of 350 mg (3.32 mmol) of2-methylpiperazine in 3 ml of dimethylformamide was slowly addeddropwise to the reaction mixture while cooling with ice (exothermicreaction). The reaction mixture was stirred for 1 hour while coolingwith ice and then stirred overnight at room temperature. After thesolvent had been evaporated to dryness, the residue was taken up inwater and this mixture was extracted three times with diethyl ether. Thecombined organic phases were dried over sodium sulfate, filtered andevaporated to dryness, with 3-methyl-1-(5-nitropyridin-2-yl)piperazine(Yield: 650 mg, 89% of theory) being obtained.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 9.0 (s, 1H); 8.2 (d, 1H); 6.6 (d, 1H),4.4 (m, 2H); 3.2 (m, 1H); 3.1 (m, 1H); 2.9 (m, 2H); 2.7 (m, 1H); 1.2 (m,3H).

¹³C-NMR (125 MHz, CDCl₃): 160.4 (C); 146.5 (CH); 134.9 (C); 133.0 (C);104.5 (CH); 52.2 (CH₂); 50.6 (CH); 45.7 (CH₂); 45.4 (CH₂); 19.6 (CH₃).

13.2 1-Allyl-2-methyl-4-(5-nitropyridin-2-yl)piperazine

630 mg (2.72 mmol) of 3-methyl-1-(5-nitropyridin-2-yl)piperazine fromExample 13.1 and 267 μl (3.09 mmol) of allyl bromide were dissolved in10 ml of dimethylformamide. 1.2 ml (8.4 mmol) of triethylamine were thenadded dropwise to the solution. After the mixture had been stirred atroom temperature for 1 hour, a further 65 μl (0.75 mmol) of allylbromide were added dropwise to the reaction mixture, which was thenstirred for a further hour. After that, a further 65 μl (0.75 mmol) ofallyl bromide and 0.5 ml (3.6 mmol) of triethylamine were addeddrop-wise. The mixture was then stirred overnight at room temperature.After the solvent had been evaporated down to dryness, the resultingresidue was taken up in water and this solution was made alkaline usinga 1N aqueous solution of sodium hydroxide. After that, the aqueousreaction mixture was extracted three times with diethyl ether. Thecombined organic phases were dried over sodium sulfate, filtered andevaporated down to dryness, with 707 mg (90% of theory) of the titlecompound being obtained.

MS [m+1]: 263.

13.3 6-(4-Allyl-3-methylpiperazin-1-yl)pyridine-3-amine

4.975 g (22.05 mmol) of tin(II) chloride dihydrate were added to asolution of 707 mg (2.45 mmol) of1-allyl-2-methyl-4-(5-nitropyridin-2-yl)piperazine from Example 13.2 in50 ml of methanol and the resulting mixture was stirred at 70° C. for 90minutes. After the solvent had been evaporated down to dryness, waterwas added to the resulting residue and the mixture was made alkalineusing a dilute aqueous solution of sodium hydroxide. After that, theaqueous reaction mixture was extracted with ethyl acetate. The solidwhich had precipitated out was filtered off with suction and the phaseswere separated. The aqueous phase was extracted with dichloromethane.After that, the combined organic phases were dried over sodium sulfate,filtered and evaporated down to dryness. The resulting title compoundwas used in the next step without any further purification.

MS [m+1]: 233.

13.4N-[6-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

305 mg (1.31 mmol) of6-(4-allyl-3-methylpiperazin-1-yl)pyridin-3-ylamine from Example 13.3and 301 mg (1.38 mmol) of 4-isopropylbenzenesulfonyl chloride weredissolved in 10 ml of tetrahydrofuran at room temperature, after which0.55 ml (3.94 mmol) of triethylamine was added dropwise. After that, thereaction mixture was stirred overnight at room temperature. After thesolvent had been evaporated down to dryness, the resulting residue wastreated with water and the mixture was made acid with 1N hydrochloricacid and extracted twice with diethylether. The aqueous phase was madealkaline, to pH 9-10, using a 1N aqueous solution of sodium hydroxideand then extracted twice with diethyl ether. After the combined organicphases had been dried over sodium sulfate and the solvent had beenfiltered and evaporated down to dryness, the resulting residue waspurified by column chromatography (cyclohexane/ethylacetate from 50:50to 20:80). After that, the filtrate was evaporated down to dryness. Theresulting residue was converted into the hydrochloride using etherealhydrochloric acid, with 417 mg (74% of theory) of the title compoundbeing obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.3 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 6.0 (m, 1H);5.5 (m, 2H); 4.3 (m, 1H); 4.0 (m, 1H); 3.7 (m, 1H); 3.4 (m, 1H); 3.2 (m,3H); 3.0 (m, 3H); 1.4 (d, 3H); 1.2 (d, 6H).

MS [m+1]: 415 (free base).

Example 13aN-{6-[4-Allyl-(3S)-methylpiperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesulfonamide(S enantiomer as free base)

The preparation was effected in analogy with the preparation of theracemic compound, with enantiomerically pure (2S)-methylpiperazine beingused in step 13.1 instead of racemic 2-methylpiperazine.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.3 (bs, 1H); 10.0 (s, 1H); 7.8 (s,1H); 7.6 (d, 2H); 7.4 (d, 1H); 7.3 (d, 1H); 6.9 (d, 1H); 6.0 (m, 1H);5.5 (m, 2H); 4.3 (m, 2H); 4.0 (m, 1H); 3.7 (m, 1H); 3.4 (m, 1H); 3.2 (m,2H); 3.1 (m, 1H); 3.0 (m, 2H).1.4 (d, 3H); 1.2 (d, 6H).

MS [m+1]: 415 (free base)

Example 144-Isopropyl-N-[6-(3-methyl-4-propylpiperazin-1-yl)pyridin-3-yl]benzenesulfonamidehydrochloride

100 mg (0.24 mmol) ofN-[6-(4-allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride from Example 13.4 were dissolved in 10 ml of ethylacetate, after which 10 mg of palladium on active charcoal (10%) wereadded and the mixture was stirred overnight at room temperature under ahydrogen atmosphere. After that, the catalyst was filtered off and thefiltrate was evaporated down to dryness. After 1 ml of dichloromethanehad been added to the resulting residue, diethyl ether was slowly addeddropwise until the solution became cloudy. The reaction mixture wasstirred for 30 minutes and the precipitate which had formed was filteredoff with suction. The filtrate was evaporated down to dryness, afterwhich the residue was dissolved in a 1:1 mixture of dichloromethane anddiethyl ether and converted into the hydrochloride by adding etherealhydrochloric acid. 71 mg (63% of theory) of the title compound wereobtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.9 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (d, 1H); 6.9 (d, 1H); 4.2 (m, 2H);3.6 (m, 1H); 3.4-3.0 (m, 7H); 1.7 (m, 2H); 1.4 (d, 3H); 1.2 (d, 6H); 0.9(m, 3H).

MS [m+1]: 417 (free base).

Example 14a4-Isopropyl-N-{6-[(3S)-methyl-4-propylpiperazin-1-yl]pyridin-3-yl}benzenesulfonamideas free base (S enantiomer)

The preparation was effected in analogy with the preparation of theracemic compound, with enantiomerically pure (2S)-methylpiperazine beingused instead of racemic 2-methylpiperazine.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 9.7 (s, 1H); 7.7 (s, 1H); 7.6 (d,2H); 7.4 (d, 2H); 7.2 (d, 1H); 6.7 (d, 1H); 3.8 (m, 2H); 2.9 (m, 2H);2.8 (m, 1H); 2.6 (m, 2H); 2.3 (m, 1H), 2.1 (m, 2H); 1.4 (m, 2H); 1.2 (d,6H); 1.0 (m, 3H); 0.8 (m, 3H).

MS [m+1-1]: 417 (free base)

Example 15N-[5-(4-Allylpiperazin-1-yl)pyridin-2-yl]-4-isopropylbenzenesulfonamidehydrochloride 15.1 1-Allyl-4-(6-nitropyridin-3-yl)piperazine

315 mg (2.5 mmol) of N-allylpiperazine were dissolved in 5 ml of tolueneunder an argon atmosphere. 93 mg (0.1 mmol) oftris-(dibenzylideneacetone)-dipalladium(0) (Pd₂ dba₃), 126 mg (0.2 mmol)of 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl (BINAP), 1.14 g (3.5mmol) of cesium carbonate and 515 mg (2.54 mmol) of5-bromo-2-nitropyridine were then added and the mixture was stirred at120° C., in a microwave oven, for 4 hours. After the reaction mixturehad cooled down to room temperature, a saturated aqueous solution ofammonium chloride was added. After that, the aqueous reaction mixturewas extracted three times with in each case 50 ml of ethyl acetate.After the organic phase had been dried over sodium sulfate, the dryingagent had been filtered off and the solvent had been evaporated down todryness, the residue was chromatographed through silica gel using ethylacetate/methanol (4:1), with 304 mg (46% of theory) of the titlecompound being obtained.

¹H-NMR (400 MHz, CDCl₃): δ [ppm] 8.2 (m, 2H); 7.2 (dd, 1H); 5.9 (m, 1H);5.3 (m, 2H); 3.5 (m, 4H); 3.1 (m, 2H); 2.6 (m, 4H).

MS [m+1]: 249

15.2 5-(4-Allylpiperazin-1-yl)pyridine-2-amine

300 mg (1.21 mmol) of 1-allyl-4-(6-nitropyridin-3-yl)piperazine fromExample 15.1 were dissolved in 20 ml of methanol, after which 2.18 g(9.67 mmol) of tin(II) chloride dihydrate were added and the mixture wasstirred at 70° C. for 2 hours. After the solvent had been evaporateddown to dryness, the resulting residue was treated with water and thismixture was made alkaline using a dilute aqueous solution of sodiumhydroxide and extracted with ethyl acetate. The solid which hadprecipitated out was filtered off with suction. The phases were thenseparated and the aqueous phase was extracted three times with ethylacetate. The combined organic phases were dried over sodium sulfate,filtered and evaporated down to dryness, with 183 mg (69% of theory) ofthe title compound being obtained.

MS [m+1]: 219.

15.3N-[5-(4-Allylpiperazin-1-yl)pyridin-2-yl]-4-isopropylbenzenesulfonamidehydrochloride

520 mg (2.38 mmol) of 5-(4-allylpiperazin-1-yl)pyridin-2-ylamine and 495mg (2.26 mmol) of 4-isopropylbenzenesulfonyl chloride were dissolved in5 ml of tetrahydrofuran at room temperature, after which 1.0 ml (7.15mmol) of triethylamine was added dropwise and the mixture was stirred at40-50° C. for 6 hours. After the solvent had been evaporated down todryness, the resulting residue was treated with water and this mixturewas made acid using 1N aqueous hydrochloric acid and extracted twicewith diethyl ether. The aqueous phase was made alkaline, to pH 9-10,using a 1N aqueous solution of sodium hydroxide and then extracted twicewith ethyl acetate. After the combined organic phases had been driedover sodium sulfate, the drying agent had been filtered off and thesolvent had been evaporated down to dryness, the resulting residue waschromatographed on silica gel using ethyl acetate. After the solvent hadbeen removed, the resulting residue was brought into solution using alittle diethyl ether in dichloromethane and then converted into thehydrochloride using ethereal hydrochloric acid. 415 mg (44% of theory)of the title compound were obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.6 (bs, 1H); 7.9 (d, 1H); 7.8 (d,2H); 7.5 (dd, 1H); 7.4 (d, 2H); 7.1 (d, 1H); 6.0 (m, 1H); 5.5 (m, 2H);3.7 (m, 4H); 3.4 (m, 2H); 3.1 (m, 4H); 3.0 (m, 1H); 1.2 (d, 6H).

¹³C-NMR (100 MHz, DMSO-d₆): δ [ppm] 153.3 (C); 144.5 (C); 141.6 (C);138.4 (C); 134.3 (CH); 127.3 (CH); 127.0 (CH); 126.8 (CH); 124.8 (CH₂);113.8 (CH); 57.3 (CH₂); 49.6 (CH₂); 45.2 (CH₂); 33.3 (CH); 23.4 (CH₃).

MS [m+1]: 401.

Example 16N-[2-(4-Allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfonamide16.1 2-(4-Allylpiperazin-1-yl)-5-nitropyrimidine

114 mg (2.38 mmol) of 50% sodium hydride were added, under a nitrogenatmosphere and while cooling with ice, to a solution of 273 mg (2.17mmol) of N-allylpiperazine in 5 ml of dimethylformamide. After 30minutes, a solution of 440 mg (2.17 mmol) of2-(methylsulfone)-5-nitropyrimidine in 5 ml of dimethylformamide wasadded dropwise to the reaction mixture. After 10 minutes, 70 ml of waterwere added and the reaction mixture was extracted twice with in eachcase 50 ml of ethyl acetate. After the combined organic phases had beendried over sodium sulfate, the drying agent had been filtered off andthe solvent had been evaporated to dryness, 535 mg (99% of theory) ofthe title compound were obtained.

¹H-NMR (400 MHz, CDCl₃): δ [ppm] 9.0 (s, 2H); 5.8 (m, 1H); 5.2 (m, 2H);4.0 (m, 4H); 3.1 (m, 2H); 2.5 (m, 4H).

MS [m+1]: 250.

16.2 2-(4-Allylpiperazin-1-yl)pyrimidine-5-amine

3.84 g (17.0 mmol) of tin(II) chloride dihydrate were added to asolution of 530 mg (2.13 mmol) of2-(4-allylpiperazin-1-yl)-5-nitropyrimidine from Example 16.1 in 20 mlof methanol and, after that, the reaction mixture was heated at refluxfor 1 hour. After the solvent had been evaporated to dryness, theresidue was treated with saturated aqueous sodium chloride solution andthen made alkaline using dilute aqueous sodium hydroxide solution. Afterthat, the aqueous reaction mixture was extracted with ethyl acetate. Thesolid which had precipitated out was filtered off with suction. Thephases were then separated and the aqueous phase was extracted in eachcase twice with ethyl acetate and dichloromethane. After the combinedorganic phases had been dried over sodium sulfate, the drying agent hadbeen filtered off and the solvent had been evaporated down to dryness,220 mg (46% of theory) of the title compound were obtained.

16.3N-[2-(4-Allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfonamide

216 mg (0.98 mmol) of 2-(4-Allylpiperazin-1-yl)pyrimidin-5-ylamine fromExample 16.2 and 215 mg (0.98 mmol) of 4-isopropylbenzenesulfonylchloride were dissolved in 20 ml of tetrahydrofuran at room temperature,after which 0.4 ml (3.0 mmol) of triethylamine was added dropwise andthe mixture was stirred at room temperature overnight. After the solventhad been evaporated down to dryness, water was added to the resultingresidue. The aqueous reaction mixture was made acid using 1N aqueoushydrochloric acid and extracted twice with diethyl ether. The aqueousphase was made alkaline to pH 9-10, using a 1N solution of sodiumhydroxide and then extracted three times with diethyl ether. Thecombined organic phases were dried over sodium sulfate. The residuewhich was obtained after filtering off the drying agent and evaporatingthe solvent down to dryness was thoroughly stirred with a mixturecomposed of heptane and diethyl ether, filtered off with suction anddried, with 71 mg (18% of theory) of the title compound being obtained.

¹H-NMR (500 MHz, CDCl₃): δ [ppm] 8.0 (s, 2H); 7.7 (d, 2H); 7.3 (d, 2H);6.2 (bs, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.8 (m, 4H); 3.1 (m, 2H); 3.0(m, 1H); 2.5 (m, 4H); 1.3 (d, 6H).

MS [m+1]: 402.

Example 174-Isopropyl-N-[2-(4-propylpiperazin-1-yl)pyrimidin-5-yl]benzenesulfonamidehydrochloride

70 mg (0.17 mmol) ofN-[2-(4-allylpiperazin-1-yl)pyrimidin-5-yl]-4-isopropylbenzenesulfonamidefrom Example 16.3 were dissolved in 30 ml of ethyl acetate, after which10 mg of palladium on active charcoal (10%) were added and the mixturewas stirred at room temperature for 2 hours under a hydrogen atmosphere.The catalyst was then filtered off and the filtrate was concentrated byevaporation. The residue was brought into solution using 25 ml ofdiethyl ether and converted into the hydrochloride with etherealhydrochloric acid, resulting in 58 mg (76% of theory) of the titlecompound being obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.0 (bs, 1H); 10.0 (s, 1H); 8.1 (s,2H); 7.7 (d, 2H); 7.5 (d, 2H); 4.6 (m, 2H); 3.5 (m, 2H); 3.4 (m, 2H);3.0 (m, 5H); 1.7 (m, 2H); 1.3 (d, 6H); 0.9 m, 3H).

MS [m+1]: 404 (free base).

Example 18N-[6-(4-Allylpiperazin-1-yl)pyrimidin-4-yl]-4-isopropylbenzenesulfonamide18.1 N-(6-Chloropyrimidin-4-yl)-4-isopropylbenzenesulfonamide

996 mg (5.0 mmol) of isopropylbenzenesulfonamide were dissolved in 20 mlof dimethyl sulfoxide, after which 288 mg (6.0 mmol) of 50% sodiumhydride were added and the mixture was stirred at room temperature for30 minutes. 819 mg (5.5 mmol) of 4,6-dichloropyrimidine were then addedand the reaction mixture was stirred overnight at room temperature.Subsequently, the mixture was heated at 90° C. for 3 hours and, afterthat, stirred at 120° C., in a microwave oven, for 30 minutes. After thereaction mixture had cooled down to room temperature, it was dilutedwith 150 ml of water, neutralized with citric acid and extracted threetimes with diethyl ether. The residue, which was obtained after dryingwith sodium sulfate and after removing the solvent, was dissolved in 100ml of diethyl ether and extracted with an aqueous solution of sodiumhydrogen carbonate. The aqueous phase was acidified and extracted withdiethyl ether. The organic phase was dried, filtered and evaporated downto dryness, with 440 mg (28% of theory) of the title compound beingobtained.

MS [m+1]: 312.

18.2N-[6-(4-Allylpiperazin-1-yl)pyrimidin-4-yl]-4-isopropylbenzenesulfonamide

430 mg (1.38 mmol) ofN-(6-chloropyrimidin-4-yl)-4-isopropylbenzenesulfonamide from Example18.1 were dissolved in 3 ml of dimethyl sulfoxide, after which 1.74 g(13.79 mmol) of N-allylpiperazine were added and the mixture was stirredovernight. Subsequently, the reaction mixture was stirred at 100° C., ina microwave oven, for 45 minutes. After the reaction mixture had cooleddown to room temperature, it was diluted with 50 ml of water. Afterthat, the aqueous reaction mixture was extracted with 50 ml of ethylacetate and the precipitate was filtered off with suction, with 190 mg(34% of theory) of the title compound being obtained.

¹H-NMR (400 MHz, CDCl₃): δ [ppm] 8.4 (s, 1H); 7.8 (d, 2H); 7.3 (d, 2H);6.1 (s, 1H); 5.9 (m, 1H); 5.2 (m, 2H); 3.6 (m, 4H); 3.0 (m, 3H); 2.5 (m,4H); 1.3 (d, 6H).

MS [m+1]: 402.

Example 19N-[2-(4-Allylpiperazin-1-yl)pyridin-5-yl]-4-bromobenzenesulfonamidehydrochloride

The preparation was effected in analogy with Example 1.3, with4-bromobenzenesulfonyl chloride being used instead of4-isopropylbenzenesulfonyl chloride. The reaction product which wasobtained was converted into the hydrochloride using etherealhydrochloric acid, resulting in 398 mg of the title compound.

MS [m+1]: 436/438

Example 20N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-cyclopropylbenzenesulfonamide

398 mg (0.84 mmol) ofN-[6-(4-allylpiperazin-1-yl)pyridin-3-yl]-4-bromobenzenesulfonamide fromExample 19, 101 mg (1.18 mmol) of cylcopropylboronic acid, 676 mg (3.19mmol) of K₃PO₄ and 26 mg (0.09 mmol) of tricyclohexylphosphine weredissolved in 4 ml of toluene and 0.2 ml of water under a nitrogenatmosphere. 10 mg (0.04 mmol) of palladium(II) acetate were then addedand the mixture was stirred at 100° C., in a microwave oven, for onehour. After the solvent had been evaporated down to dryness, theresulting residue was treated with water and the mixture was thenextracted with ethyl acetate. Because the phases only separated poorly,the finely divided solid was filtered off. The aqueous phase wasextracted twice with ethyl acetate. After the combined organic phaseshad been dried over sodium sulfate and the solvent had been filtered andevaporated down to dryness, the resulting residue was purified by columnchromatography.

MS [m+1]: 399

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.1 (bs, 1H); 9.9 (s, 1H); 7.8 (s,1H); 7.6 (d, 2H); 7.3 (dd, 1H); 7.2 (d, 2H); 6.9 (d, 1H); 6.0 (m, 1H);5.5 (d, 2H); 4.3 (m, 2H); 3.8 (m, 2H); 3.4 (m, 2H); 3.2 (m, 2H); 3.0 (m,2H); 2.0 (m, 1H); 1.0 (m, 2H); 0.8 (m, 2H).

The compounds of the following examples 21 to 40 were prepared inanalogous manner:

Example 214-Isopropyl-N-[2-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamidehydrochloride

MS [m+1]: 403 (free base).

Example 224-Isopropyl-N-[2-(3,5-dimethyl-4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamidetrifluoroacetate

MS [m+1]: 431 (free base).

Example 23N-[2-(4-Allyl-3-methylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonamidehydrochloride

MS [m+1]: 441 (free base).

Example 24N-[6-(4-Allyl-3,5-dimethylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

MS [m+1]: 429 (free base)

Example 25N-[6-(4-Allyl-3,5-dimethylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonamidehydrochloride

MS [m+1]: 455 (free base)

Example 26N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-trifluoromethylbenzenesulfonamide

MS [m+1]: 427

Example 274-Bromo-N-[6-(4-propylpiperazin-1yl)pyridin-3-yl]-benzenesulfonamide

MS [m+1]: 439/441

Example 284-Chloro-N-[6-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamide

MS [m+1]: 395

Example 294-Isopropyl-N-[6-(5-propyl-2,5-diazabicyclo[2.2.1]hept-2-yl)pyridin-3-yl]-benzenesulfonamidehydrochloride

MS [m+1]: 415 (free base)

Example 30N-[6-(5-Allyl-2,5-diazabicyclo[2.2.1]hept-2-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

MS [m+1]: 413 (free base)

Example 31N-[6-(4-Propylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonamidehydrochloride

MS [m+1]: 387 (free base)

Example 32N-{6-[4-(3-Fluoropropyl)piperazin-1-yl]pyridin-3-yl}-4-isopropylbenzene-sulfonamidehydrochloride

MS [α]+1]: 421 (free base)

Example 334-Isopropyl-N-[6-(4-prop-2-yn-1-ylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamidehydrochloride

MS [m+1-1]: 399 (free base)

Example 344-Ethyl-N-[6-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamidehydrochloride

MS [m+1]: 389 (free base)

Example 35N-[6-(4-Allylpiperazin-1-yl)pyridin-3-yl]-4-chlorobenzenesulfonamidehydrochloride

MS [m+1]: 393 (free base)

Example 364-Isopropyl-N-(4-methyl-6-piperazin-1-ylpyridin-3-yl)-benzenesulfonamidehydrochloride

MS [m+1]: 375 (free base)

Example 37N-[6-(4-Allylpiperazin-1-yl)-4-methylpyridin-3-yl]-4-isopropylbenzene-sulfonamidehydrochloride

MS [m+1]: 415 (free base)

Example 384-Isopropyl-N-[4-methyl-6-(4-propylpiperazin-1-yl)pyridin-3-yl]-benzenesulfonamidehydrochloride

MS [m+1]: 417 (free base)

Example 39N-[4-Methyl-6-(4-propylpiperazin-1-yl)pyridin-3-yl]-4-vinylbenzenesulfonamidehydrochloride

MS [m+1]: 401 (free base)

Example 40N-[6-(4-Butylpiperazin-1-yl)pyridin-3-yl]-4-isopropylbenzenesulfonamidehydrochloride

MS [m+1]: 417 (free base)

Example 41N-{6-[(3S)-4-Ethyl-3-methylpiperazin-1-yl]pyridin-3-yl}-4-isopropylbenzenesulfonamidehydrochloride

MS [m+1]: 403 (free base)

Example 42N-[2-(4-Allylpiperazin-1-yl)pyridin-5-yl]-4-(N-pyrrolidinyl)benzene-sulfonamidefumarate

Reaction of 0.300 g of 6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine(1.29 mmol) and 0.282 g of 4-isopropylbenzene-1-sulfonyl chloride (1.29mmol) in 10 ml of a mixture of pyridine and dichloromethane (1:2)yielded 0.465 g (87%) of the title compound as a white solid. The titlecompound was onverted into the fumarate salt in methanol by addition offumaric acid.

MS [m+1]: 415

¹H-NMR (400 MHz, CH₃OD): δ [ppm]: 7.6 (d, 2H), 7.5 (d, 2H), 7.3 (m, 1H),7.2 (m, 1H), 7.1 (d, 1H), 6.5 (d, 1H), 5.9 (m, 1H), 5.4 (m, 2H), 3.5 (m,5H), 3.0 (m, 4H), 2.8 (m, 2H), 1.9 (s, 3H), 1.2 (m, 6H).

Example 434-Isopropyl-[N-[2-(4-allylpiperazin-1-yl)-6-methylpyridin-5-yl]-4-(N-pyrrolidinyl)benzenesulfonamide,Fumarate

Reaction of 0.300 g of 6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine(1.29 mmol) and 0.282 g of 4-isopropylbenzene-1-sulfonyl chloride (1.29mmol) in 10 ml of a mixture of pyridine/dichloromethane (1:2) yielded0.465 g (87%) of the title compound as a white solid. The title compoundwas onverted into the fumarate salt in methanol by addition of fumaricacid.

MS [m+1]: 415

¹H-NMR (400 MHz, MeOD): δ [ppm] 7.6 (d, 2H), 7.5 (d, 2H), 7.3 (m, 1H),7.2 (m, 1H), 7.1 (d, 1H), 6.5 (d, 1H), 5.9 (m, 1H), 5.4 (m, 2H), 3.5 (m,5H), 3.0 (m, 4H), 2.8 (m, 2H), 1.9 (s, 3H), 1.2 (m, 6H).

Example 444-tert-Butyl-N-[2-(4-allylpiperazin-1-yl)-6-methylpyridin-5-yl]-benzenesulfonamide,fumarate

Reaction of 0.300 g of 6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine(1.29 mmol) and 0.300 g of 4-tert-butylbenzene-1-sulfonyl chloride (1.29mmol) in 10 ml of a mixture of pyridine/dichloromethane (1:2) yielded0.525 g (95%) of the title compound as a white solid. The title compoundwas onverted into the fumarate salt in methanol by addition of fumaricacid.

MS [m+1]: 429

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 9.3 (s, 2H), 8.6 (d, 2H), 7.8 (m,1H), 7.4 (m, 2H), 7.0 (d, 1H), 6.6 (d, 1H), 5.8 (m, 1H), 5.2 (m, 2H),3.4 (m, 4H), 2.9 (m, 2H), 2.4 (m, 4H), 1.9 (s, 3H), 1.3 (s, 9H).

Example 454-tert-pentyl-[N-[2-(4-Allylpiperazin-1-yl)-6-methylpyridin-5-yl]-benzenesulfonamide,Fumarate

Reaction of 0.300 g of 6-(4-allylpiperazin-1-yl)-2-methylpyridin-3-amine(1.29 mmol) and 0.318 g of 4-tert-pentylbenzene-1-sulfonyl chloride(1.29 mmol) in 10 mL pyridine-dichloromethane (1:2) yielded 0.564 g(99%) of the title compound as a white solid. The title compound wasonverted into the fumarate salt in methanol by addition of fumaric acid.

MS [m+1]: 443

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 9.3 (s, 2H), 8.6 (d, 2H), 7.8 (m,1H), 7.4 (m, 2H), 7.0 (d, 1H), 6.5 (d, 1H), 5.8 (m, 1H), 5.2 (m, 2H),3.4 (m, 4H), 3.0 (m, 2H), 2.4 (m, 4H), 1.9 (s, 3H), 1.6 (m, 2H), 1.2 (s,6H), 0.6 (t, 3H).

The compounds of Examples 46 to were prepared in analogous manner:

Example 464-Ethyl-N-[6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.9 (bs, 1H); 10.0 (s, 1H); 7.8 (m,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (dd, 1H); 6.9 (d, 1H); 4.3 (m, 2H);3.5-2.9 (m, 7H); 2.7 (m, 2H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 4H); 0.9(t, 3H).

MS [m+1]: 403

Example 47N-[6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-4-vinylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.4 (bs, 1H); 10.0 (s, 1H); 7.8 (s,1H); 7.7 (m, 4H); 7.3 (d, 1H); 6.9 (d, 1H); 6.8 (dd, 1H); 6.0 (d, 1H);5.4 (d, 1H); 4.3 (m, 2H); 3.5 (m, 1H); 3.3-2.9 (m, 6H); 1.7 (m, 2H); 1.4(m, 2H); 1.2 (m, 1H); 0.9 (t, 3H).

MS [m+1]: 401

Example 48N-[6-((S)-4-Allyl-3-methyl-piperazin-1-yl)-2-methoxy-pyridin-3-yl]-4-isopropyl-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.1 (bs, 1H); 9.2 (s, 1H); 7.6 (d,2H); 7.4 (d, 2H); 7.3 (m, 1H); 6.4 (m, 1H); 6.0 (m, 1H); 5.5 (m, 2H);4.3 (m, 2H); 4.0 (m, 1H); 3.7 (m, 2H); 3.4-3.2 (m, 5H); 3.1 (m, 1H); 3.0(m, 2H); 1.4 (m, 2H); 1.2 (m, 7H).

MS [m+1]: 445

Example 494-Isopropyl-N-[2-methoxy-6-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.8 (bs, 1H); 9.3 (s, 1H); 7.6 (d,2H); 7.4 (d, 2H); 7.3 (m, 1H); 6.4 (m, 1H); 4.2 (m, 2H); 3.5-3.2 (m,8H); 3.1 (m, 1H); 3.0 (m, 2H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 7H);0.9 (t, 3H).

MS [m+1]: 447

Example 50N-[6-((S)-4-Allyl-3-ethyl-piperazin-1-yl)-pyridin-3-yl]-4-isopropylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.2 (bs, 1H); 10.0 (s, 1H); 7.8 (d,1H); 7.6 (d, 2H); 7.4 (d, 2H); 7.3 (m, 1H); 6.9 (d, 1H); 6.0 (m, 1H);5.5 (m 2H); 4.2 (m, 2H); 4.0 (m, 2H); 3.4-3.0 (m, 6H); 1.7 (m, 2H); 1.2(d, 6H); 1.0 (t, 3H).

MS [m+1]: 429

Example 51N-[6-((S)-3-Ethyl-4-propyl-piperazin-1-yl)-pyridin-3-yl]-4-isopropylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.2 (bs, 1H); 10.2 (s, 1H); 7.8 (d,1H); 7.7 (d, 2H); 7.4 (m, 3H); 7.0 (d, 1H); 4.2 (m, 2H); 3.6-3.0 (m,8H); 2.0 (m, 1H); 1.7 (m, 3H); 1.2 (d, 6H); 1.0 (m, 6H).

MS [m+1]: 431

Example 524-Isopropyl-N-(2-piperazin-1-yl-pyrimidin-5-yl)-benzenesulfonamide

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 8.0 (s, 2H); 7.6 (d, 2H); 7.4 (d,2H); 3.6 (m, 4H); 3.0 (m, 1H); 2.7 (m, 4H); 1.2 (d, 6H).

MS [m+1]: 362

Example 53N-[2-(4-Ethyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropyl-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, D₂O): δ [ppm] 7.7 (s, 2H); 7.3 (d, 2H); 7.1 (d, 2H);4.3 (m, 2H); 3.3 (m, 2H); 3.0 (m, 4H); 2.7 (m, 3H); 1.0 (t, 3H); 0.9 (d,6H).

MS [m+1]: 390

Example 54N-[2-((S)-4-Ethyl-3-methyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.7 (bs, 1H); 10.0 (s, 1H); 8.1 (m,2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.6 (m, 2H); 3.4 (m, 4H); 3.2 (m, 1H);3.0 (m, 3H); 1.4 (m, 2H); 1.2 (m, 10H).

MS [m+1]: 404

Example 55N-[2-((S)-4-Allyl-3-methyl-piperazin-1-yl)-pyrimidin-5-yl]-4-isopropylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.0 (bs, 1H); 10.0 (s, 1H); 8.1 (s,2H); 7.6 (d, 2H); 7.4 (d, 2H); 6.0 (m, 1H); 5.5 (m, 2H); 4.6 (m, 2H);4.0 (m, 2H); 3.7 (m, 2H); 3.3 (m, 3H); 3.0 (m, 1H); 1.4 (m, 2H); 1.2 (m,7H).

MS [m+1]: 416

Example 564-Isopropyl-N-[2-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.6 (bs, 1H); 10.0 (s, 1H); 8.1 (m,2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.5 (m, 2H); 3.5 (m, 2H); 3.3 (m, 3H);3.0 (m, 3H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 7H); 0.9 (t, 3H).

MS [m+1]: 418

Example 574-Ethyl-N-[2-((S)-3-methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]-benzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.8 (bs, 1H); 10.0 (s, 1H); 8.1 (m,2H); 7.6 (d, 2H); 7.4 (d, 2H); 4.5 (m, 2H); 3.5 (m, 2H); 3.3 (m, 3H);3.0 (m, 2H); 2.7 (m, 2H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m, 4H); 0.9 (t,3H).

MS [m+1]: 404

Example 58N-[2-((S)-3-Methyl-4-propyl-piperazin-1-yl)-pyrimidin-5-yl]-4-vinylbenzenesulfonamide,hydrochloride

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 10.7 (bs, 1H); 10.0 (s, 1H); 8.1 (d,2H); 7.7 (m, 4H); 6.8 (dd, 1H); 6.0 (d, 1H); 5.5 (d, 1H); 4.5 (m, 2H);3.5 (m, 2H); 3.3 (m, 3H); 3.0 (m, 2H); 1.7 (m, 2H); 1.4 (m, 2H); 1.2 (m,1H); 0.9 (t, 3H).

MS [m+1]: 402

Example 59 4-Isopropyl-benzenesulfonic acid6-(4-allyl-piperazin-1-yl)-pyridin-3-yl ester

59.1 4-Isopropyl-benzenesulfonic acid 6-chloro-pyridin-3-yl ester

A reaction flask containing 500 mg of 6-chloropyridin-3-ol (3.86 mmol)and 844 mg of 4-isopropyl-benzenesulfonylchloride (0.20 mmol) in drytetrahydrofurane (10 ml) was flushed with N₂. 1.6 ml of triethylaminewere added and the reaction mixture was stirred at room temperature for2 h. Thereby 4-isopropyl-benzenesulfonic acid 6-chloropyridin-3-yl esterester was obtained in 98% yield.

MS [m+1]: 312

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 8.1 (d, 1H); 7.8 (d, 2H); 7.6 (m,4H); 3.0 (m, 1H); 1.2 (d, 6H).

59.2 4-Isopropyl-benzenesulfonic acid6-(4-allyl-piperazin-1-yl)-pyridin-3-yl ester

A flask containing 45 mg of palladium(II) acetate (0.2 mmol), 126 mg ofBINAP (0.20 mmol) and 0.233 mg of sodium tert-butylate in dry toluene(15 mL) was flushed with nitrogen 1.275 g of 1-allylpiperazin (10 mmol)were added and the reaction mixture was heated to 50° C. 630 mg of4-isopropyl-benzenesulfonic acid 6-chloro-pyridin-3-yl ester (2.0 mmol)were dissolved in toluene and the solution was slowly added over aperiod of 10 minutes into the reaction mixture with stirring. Themixture was heated to reflux with stirring for 7 h. Thereby4-isopropyl-benzenesulfonic acid 6-(4-allyl-piperazin-1-yl)-pyridin-3-ylester was obtained in 21% yield.

MS [m+1]: 402

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 7.8 (d, 2H); 7.7 (d, 1H); 7.6 (d,2H); 7.2 (dd, 1H); 6.8 (d, 1H); 5.8 (m, 1H); 5.2 (m, 2H); 3.5 (m, 4H);3.0 (m, 3H); 2.5 (m, 4H); 1.2 (d, 6H).

Example 60 4-Isopropyl-benzenesulfonic acid6-(4-propyl-piperazin-1-yl)-pyridin-3-yl ester, hydrochloride

In a reaction flask 5 mg of palladium on charcoal were added to 50 mg of4-isopropylbenzenesulfonic acid 6-(4-allyl-piperazin-1-yl)-pyridin-3-ylester from example 59(0.12 mmol) in dry ethyl acetate (5 ml). Theatmosphere was then charged with hydrogen gas and the reaction mixturewas stirred at room temperature for 1 hour. Thereby,4-isopropyl-benzenesulfonic acid6-(4-propyl-piperazin-1-yl)-pyridin-3-yl ester were obtained in 58%yield. The compound was converted into its hydrochloride salt byaddition of HCl in ether.

MS [m+1]: 404

¹H-NMR (400 MHz, DMSO-d₆): δ [ppm] 11.0 (bs, 1H); 7.8 (m, 3H); 7.6 (d,2H); 7.3 (dd, 1H); 6.9 (d, 1H); 4.3 (d, 2H); 3.5 (d, 2H); 3.3 (dd, 2H);3.0 (m, 5H); 1.7 (m, 2H); 1.3 (d, 6H); 0.9 (t, 3H).

Examples of galenic administration forms

A) Tablets

Tablets of the following composition are pressed on a tablet press inthe customary manner:

-   -   40 mg of substance from Example 2    -   120 mg of corn starch    -   13.5 mg of gelatin    -   45 mg of lactose    -   2.25 mg of Aerosil® (chemically pure silicic acid in        submicroscopically fine dispersion)    -   6.75 mg of potato starch (as a 6% paste)

B) Sugar-Coated Tablets

20 mg of substance from Example 2

60 mg of core composition

70 mg of saccharification composition

The core composition consists of 9 parts of corn starch, 3 parts oflactose and 1 part of 60:40 vinylpyrrolidone/vinyl acetate copolymer.The saccharification composition consists of 5 parts of cane sugar, 2parts of corn starch, 2 parts of calcium carbonate and 1 part of talc.The sugar-coated tablets which had been prepared in this way aresubsequently provided with a gastric juice-resistant coating.

Biological Investigations—Receptor Binding Studies:

The substance to be tested was either dissolved in methanol/Chremophor®(BASF-AG) or in dimethyl sulfoxide and then diluted with water to thedesired concentration.

Dopamine D₃ receptor:

The assay mixture (0.250 ml) was composed of membranes derived from ˜10⁶HEK-293 cells possessing stably expressed human dopamine D₃ receptors,0.1 nM [¹²⁵I]-iodosulpride and incubation buffer (total binding) or, inaddition, test substance (inhibition curve) or 1 μM spiperone(nonspecific binding). Each assay mixture was run in triplicate.

The incubation buffer contained 50 mM tris, 120 mM NaCl, 5 mM KCl, 2 mMCaCl₂, 2 mM MgCl₂ and 0.1% bovine serum albumin, 10 μM quinolone and0.1% ascorbic acid (prepared fresh daily). The buffer was adjusted to pH7.4 with HCl.

Dopamine D_(2L) Receptor:

The assay mixture (1 ml) was composed of membranes from ˜10⁶ HEK-293cells possessing stably expressed human dopamine D_(2L) receptors (longisoform) and 0.01 nM [¹²⁵I] iodospiperone and incubation buffer (totalbinding) or, in addition, test substance (inhibition curve) or 1 μMhaloperidol (nonspecific binding). Each assay mixture was run intriplicate.

The incubation buffer contained 50 mM tris, 120 mM NaCl, 5 mM KCl, 2 mMCaCl₂, 2 mM MgCl₂ and 0.1% bovine serum albumin. The buffer was adjustedto pH 7.4 with HCl.

Measurement and Analysis:

After having been incubated at 25° C. for 60 minutes, the assay mixtureswere filtered through a Whatman GF/B glass fiber filter under vacuumusing a cell collecting device. The filters were transferred toscintillation viols using a filter transfer system. After 4 ml of UltimaGold® (Packard) have been added, the samples were shaken for one hourand the radioactivity was then counted in a Beta-Counter (Packard,Tricarb 2000 or 2200CA). The cpm values were converted into dpm using astandard quench series and the program belonging to the instrument.

The inhibition curves were analyzed by means of iterative nonlinearregression analysis using the Statistical Analysis System (SAS) which issimilar to the “LIGAND” program described by Munson and Rodbard.

In these tests, the compounds according to the invention exhibit verygood affinities for the D₃ receptor (<100 nM, frequently <50 nM) andbind selectively to the D₃ receptor. The results of the binding testsare given in Table 1.

TABLE 1 K_(i) (D₃) Selectivity Example [nM] vs. D₂L*  1  3.0 232  2  5.5 25  3  5.9  15  5 11.4 108  6  9.7 169  7 11.4  68 10  7.5  93 11  6.2 77 13  3.6 131 13a  2.7  96 14  2.5  81 14a  1.5 184 16  3.8 131 17 8.2 148 19 36.9  91 22 21.9  22 24 25.0  47 27 21.4  55 28 25.3  67 2916.9  31 30 11.1  17 31 14.0  96 32 17.0  74 34  9.6  73 35 26.6  51 36 5.4  50 37  2.7  86 38 17.2  22 39 34.6  30 42  5.3  33 43  1.1  80 44 1.4  41 45  1.4  24 46  7.1  50 47  6.1 118 48  0.8  21 49  0.4  19 50 9.9  57 51  3.1 101 52 14.2  63 53  8.8 149 54  2.3  84 55  2.9 159 56 1.6 399 57  7.3 234 58  6.2 254 59 16.2  75 60 17.4  47*K_(i)(D₃)/K_(i)(D_(2L))

1. An N-[(piperazinyl)hetaryl]arylsutfonamide compound of the generalformula 1

in which. R is oxygen, a group N—R³ or a group CR^(3a)R^(3b); Q is abivalent, 6-membered heteroaromatic radical which possesses 1 or 2 Natoms as ring members and which optionally carries one or twosubstituents R^(a) which is/are selected, independently of each other,from halogen, CN, NO₂, CO₂R⁴, COR⁵, C₁-C₄alkoxy, C₁-C₄-haloalkyl, NH₂,NHR⁶, NR⁶R⁷ and C₁-C₄-haloalkoxy; Ar is phenyl or a 6-memberedheteroaromatic radical which possesses 1 or 2 N atoms as ring membersand which optionally carries one or two substituents R^(b), which is/areselected from halogen, NO₂, CN, CO₂R⁴, COR⁵, NH₂, NHR⁶, NR⁶R⁷,C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy,C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkoxy,C₃-C₆-cycloalkyl-C₁-C₄-alkyl and C₁-C₄-haloalkyl, with it also beingpossible for two radicals R^(b) which are bonded to adjacent C atoms ofAr to be together C₃-C₄-alkylene; n is 0, 1 or 2; R¹ is hydrogen,C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl,C₃-C₆-cycloalkyl-C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl,C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkynyl; R² isC₁-C₄-alkyl or, together with R¹, is C₂-C₅-alkylene or, in the case ofn=2, the two radicals R² can together be C₁-C₄-allylene; R³ is hydrogenor C₁-C₄-alkyl; R^(3a), R^(3b) are, independently of each other,hydrogen or C₁-C₄-alkyl; R⁴ is C₁-C₄-alkyl, C₁-C₄-haloalkyl,C₂-C₄-alkenyl C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl-C₁-C₄-alkyl, phenyl orbenzyl; and R⁵ is hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenylC₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl-C₁-C₄-alkyl, phenyl or benzyl; R⁶, R⁷are each independently selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl ortogether with the nitrogen to which they are bound form a saturated 3-,4-, 5- or 6-membered heterocycle, which additionally may comprise anoxygen atom or an additional nitrogen atom as a ring member and whichmay carry 1, 2, 3 or 4 C₁-C₄ alkyl groups; the N-oxides thereof and thephysiologically tolerated acid addition salts of these compounds; withthe exception of the compounds:4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamideand4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.2. The compound as claimed in claim 1, wherein R is N—R³ with R³ being Hor C₁-C₄-alkyl.
 2. The compound as claimed in claim 2, wherein Q is abivalent, 6-membered heteroaromatic radical which possesses 1 or 2 Natoms as ring members and which optionally carries one or twosubstituents R^(a) which is/are selected, independently of each other,from halogen, CN, NO₂, CO₂R⁴, COR⁵, C₁-C₄-alkyl and C₁-C₄-haloalkyl andAr is phenyl or a 6-membered heteroaromatic radical which possesses 1 or2 N atoms as ring members and which optionally carries one or twosubstituents R^(b), which is/are selected from halogen, NO₂, CN, CO₂R⁴,COR⁵, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl,C₃-C₆-cycloalkyl-C₁-C₄-alkyl and C₁-C₄-haloalkyl, with it also beingpossible for two radicals R^(b) which are bonded to adjacent C atoms ofAr to be together C₃-C₄-alkylene.
 3. The compound as claimed in claim 1,in which the piperazine ring is bonded to the heteroaromatic radical Qin the para position in relation to the group R—SO₂—Ar.
 4. The compoundof claim 1, in which Q is a radical of the formula

in which A₁, A₂ and A₃ are, independently of each other, N or CH, one ortwo of the variables A₁, A₂ and A₃ can also be C—R^(a), k=0 or 1 andR^(a) is selected from halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,C₁-C₄-alkoxy, NH₂, NHR⁶, NR⁶R⁷ and C₁-C₄-haloalkoxy, with A₁, A₂ and A₃not simultaneously being N or simultaneously being selected from CH andC—R^(a).
 5. The compound as claimed in claim 4, in which A₃ is nitrogen,A₂ is CH and A₁ is N or CH and wherein the piperazine radical is locatedin the 2 position.
 6. The compound as claimed in claim 5, in which Q ispyridin-2,5-diyl which carries the piperazine radical in the 2 position.7. The compound as claimed in claim 5, in which Q is a radical of theformula

in which A₁ and A₂ are, independently of each other, N or CH and R^(a)is selected from, C₁-C₄-alkoxy, NH₂, NHR⁶, NR⁶R⁷ and C₁-C₄-haloalkoxy.8. The compound as claimed in claim 7, in which A₁ is N or CH and A₂ isCH and wherein the piperazine radical is located in the 2 position. 9.The compound of claim 1, in which the radical Ar carries a substituentR^(b) in the para position and, where appropriate, a further substituentR^(b) in the meta position or in the ortho position, in each case basedon the binding site of the sulfonamide group.
 10. The compound of claim1, in which Ar is phenyl or pyridyl, which radicals possess, whereappropriate, one or 2 R^(b) substituents.
 11. The compound of claim 1,in which R¹ is different from hydrogen and methyl.
 12. The compound asclaimed in claim 1 of the general formula 1a

in which n, R¹, R², R³, R^(a) and R^(b) have the meanings given in claim1 and in which either A₁, A₂ and A₃ are, independently of each other, Nor CH and one or two of the variables A₁, A₂ and A₃ can also be C—R^(a),with A₁, A₂ and A₃ not simultaneously being N or simultaneously beingselected from CH and C—R^(a), X and Y are selected from CH, C—R^(b′).and N, in which R^(b′) is halogen, methyl, CN, difluoromethyl ortrifluoromethyl, with X and Y not simultaneously being N orsimultaneously being C—R^(b′), and k is 0 or
 1. 13. The compound of theformula Ia as claimed in claim 12, in which k=0, with A₁, A₂ and A₃being, independently of each other, N or CH and A₁, A₂ and A₃ notsimultaneously being. N or simultaneously being CH.
 14. The compound ofthe formula 1a as claimed in claim 13, in which A₁ is CH or N, A₂ is CHand A₃ is N.
 15. The compound of the formula 1a as claimed in claim 12,in which k is 1, A₁ is CH or N, A₂ is CH and A₃ is N, and R^(a) isselected from, C₁-C₄alkoxy, NH₂, NHR⁶, NR⁶R⁷ and C₁-C₄-haloalkoxy andR^(a) is bound to the carbon atom adjacent to A₃.
 16. The compound ofthe formula 1a of claim 12, in which n is 0 or 1 and, in the case ofn=1, R² is bonded to the C atom of the piperazine ring which is adjacentto the group R¹—N and is a methyl group having the S configuration. 17.The compound of the formula 1a of claim 12, in which the radical Arcarries a substituent R^(b) in the pare position and, where appropriate,a further substituent R^(b) in the meta position or in the orthoposition, in each case based on the binding site of the sulfonamidegroup.
 18. The compound of the formula 1a of claim 12, in which Ar isphenyl or pyridyl, which radicals possess, where appropriate, one or 2R^(b) substituents.
 19. The compound of the formula 1a of claim 12, inwhich R¹ is different from hydrogen and methyl.
 20. The compound of theformula 1a of claim 12, of the general formula Ia.1

in which n, X, Y, R¹, R², R³, R^(a) and R^(b) have the meanings given inclaim 12 and q is 0, 1 or
 2. 21. The compound of the formula 1a of claim12, of the general formula 1a.2

in which n, X, Y, R¹, R², R³, R^(a) and R^(b) have the meanings given inclaim 12 and q is 0 or
 1. 22. A pharmaceutical composition whichcomprises at least one N-[(piperazinyl)hetaryl]aryl-sulfonamide compoundof claim 1 and/or at least one physiologically tolerated acid additionsalt of 1 and/or an N-oxide of 1, where appropriate together withphysiologically acceptable carriers and/or auxiliary substances.
 23. Themethod of at least one N-[(piperazinyl)hetaryl]arylsulfonamide compoundof the formula 1

in which Q, Ar, n, R¹, R² and R³ have the previously mentioned meanings,of the N-oxides thereof and of the physiologically tolerated acidaddition salts thereof for producing a pharmaceutical composition fortreating diseases which respond to influencing by dopamine D₃ receptorantagonists or dopamine D₃ agonists.
 24. The method as claimed in claim23 for treating diseases of the central nervous system.
 25. The methodas claimed in claim 23 for treating kidney function disturbances.
 26. Amethod for treating a medical disorder susceptible to treatment with adopamine D₃ receptor antagonist or a dopamine D₃ agonist, said methodcomprising administering an effective amount of at least one compound ofthe formula 1

in which Q, Ar, n, R¹, R² and R³ have the previously mentioned meanings,or the N-oxides thereof or the physiologically tolerated acid additionsalts thereof to a subject in need thereof.
 27. The method as claimed inclaim 26, wherein the medical disorder is a disease of the centralnervous system.